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Abstract
Stem cell transplantation is under investigation to stimulate angiogenesis in patients with
peripheral artery disease. To develop a cell-delivery platform that enhances cell retention
and function post-transplantation, the response of human adipose-derived stem/stromal
cells (ASCs) encapsulated within N-methacrylate glycol chitosan (MGC) hydrogels with
or without integrin-binding RGD or IKVAV motifs was explored. ASC viability was
enhanced in the MGC and MGC-RGD hydrogels relative to the MGC-IKVAV group
under hypoxic (2% O2) culture conditions, with cell spreading and higher metabolic
activity noted in MGC-RGD at 14 days. Analysis of angiogenic gene expression revealed
similar patterns between all hydrogel groups, with higher levels of the pro-angiogenic
factors HGF, VEGFA, ANGPTL4 and ANGPT2 in 3-D versus 2-D cultures.
Characterization of the in vivo response following subcutaneous implantation in
NOD/SCID mice showed enhanced ASC retention in MGC-RGD, with increased periimplant CD31+ cell recruitment in the ASC-seeded MGC and MGC-RGD hydrogels
relative to unseeded controls.

Keywords
Peripheral artery disease, cell-based therapy, adipose-derived stem/stromal cells,
injectable biomaterials, scaffold-based cell-delivery system, N-methacrylate glycol
chitosan hydrogel, integrin-binding peptides, RGD, IKVAV, therapeutic angiogenesis.
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Chapter 1

1

INTRODUCTION

1.1 Clinical Significance
1.1.1

Peripheral Artery Disease (PAD)

Affecting an estimated 800,000 Canadians and over 9 million Americans, peripheral
artery disease (PAD) is prevalent in North America.1 PAD is the manifestation of
systemic atherosclerosis resulting in the obstruction of arteries that supply blood to
organs other than the heart, with the lower extremities being the most commonly affected
site.1,2 Atherosclerosis is a progressive disease characterized by excessive accumulation
of lipid deposits, fibrous tissue, and inflammatory cells in the lumen of arteries and
arterioles.3 The build-up of atherosclerotic plaques in the peripheral arteries reduces
oxygenated and nutrient-rich blood flow to vascular beds in the extremities, causing
patients to develop disabling complications such as pain with walking (intermittent
claudication; IC) and peripheral neuropathy.4 The significant restriction of blood flow to
the periphery can result in critical limb ischemia (CLI)—the most severe form of PAD,
which can lead to resting limb pain, non-healing ulcerations that are prone to infection,
and tissue necrosis.2,5
PAD has been termed a ‘silent’ cardiovascular disease because many patients do not seek
treatment until the condition progresses to advanced stages, along with other
cardiovascular comorbidities.1 While the incidence of PAD increases significantly with
age, its prominent risk factors include smoking, diabetes mellitus, hypercholesterolemia,
chronic kidney disease, hypertension, metabolic syndrome and obesity.1,6 Combined with
the aging population, sedentary lifestyle and increasing burden of atherosclerotic risk
factors, the incidence of PAD is expected to rise dramatically over the next 10 years.1

1.1.2

Pathophysiology of PAD

PAD pathophysiology is a chronic and complex process affecting the macro- and
microvasculature of peripheral tissues.2 The blood supply from the abdominal aorta
divides at the iliac artery to enter the legs, and then runs serially through the superficial
1

femoral artery in the thigh into the popliteal artery at the knee in a single continuous
vessel with very few branches.7 In the majority of patients with symptomatic PAD, there
is significant occlusion of the iliac, femoral and/or infrapopliteal arteries.8,9 A chronic
state of ischemia is established due to reduced perfusion pressure in the distal
vasculature.10,11 Compensatory mechanisms cause the peripheral arterioles to maximally
vasodilate due to the chronic exposure to vasorelaxing factors, subsequently resulting in a
lack of tone in the blood vessels (vasomotor paralysis).11 These structural and functional
alterations result in the inability to regulate blood hydrostatic pressure, leading to
endothelial cell (EC) damage and edema in the distal portion of the limb, further
impairing the compromised microvasculature.5,11 While a healthy endothelium aids in the
modulation of vascular tone and permeability, EC damage resulting from chronic
ischemia increases free radical production, impairs nitric oxide (NO) regulation, causes
inappropriate platelet activation and leukocyte adhesion, and contributes to the formation
of microthrombi.5,11 Overall, blood flow abnormalities impair oxygen and nutrient
exchange at the capillary level, leading to increased inflammation, apoptosis, and tissue
necrosis.5

1.1.3

Current Treatments for PAD

The current treatments for PAD include lifestyle modifications and pharmacotherapy to
improve cardiovascular risk factors, with advanced cases requiring invasive surgical or
endovascular interventions such as balloon angioplasty, stenting, or surgical bypass to
restore peripheral blood flow.4 While endovascular treatments or bypass grafting can
improve arterial resistance, blood perfusion is often not fully restored in the affected
limbs

and

post-operative

edema

is

common

due

to

the

impaired

distal

microvasculature.12,13 Therefore, many patients with CLI are not candidates for surgical
revascularization or endovascular angioplasty due to diffuse atherosclerosis, and limb
amputation is required in ~25% of patients within the first year of diagnosis.14
Amputation has a detrimental impact on the quality of life, and is associated with high
morbidity and mortality rates.14 Perioperative mortality for below- and above-the-knee
amputations is between 5-20%, with a two-year mortality rate of up to 30% postamputation.10,15 Furthermore, many survivors require a secondary amputation and less
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than 50% of the patients recover full mobility.16 CLI also places a considerable economic
burden on the healthcare system attributed to prolonged hospitalization, complex wound
care, and invasive surgical procedures.17 Taken together, there is a critical need to
develop improved therapies to treat CLI.

1.2 In Vivo Response to Tissue Ischemia
Under pathological conditions such as obstructive arterial disease, oxygenated blood and
nutrient exchange is unable to meet the metabolic demands of the surrounding tissues.2
As a result, the body initiates several compensatory mechanisms in an attempt to restore
circulation to the ischemic tissues by inducing structural and functional changes in the
existing vasculature, or by stimulating new blood vessel formation.2

1.2.1

Angiogenesis

Angiogenesis is a multi-step process involving the growth of new blood vessels from preexisting vessels through a series of stages including EC proliferation and migration,
abluminal sprouting, and bridging of existing vessels.16 The process of angiogenesis is
tightly regulated by key pro- and anti-angiogenic molecules that function to advance or
regress blood vessels through the stroma (Table 1.1).18 In a model first proposed by Judah
Folkman,19 the angiogenic switch is considered “off” when the effects of the proangiogenic factors are balanced with those of the anti-angiogenic factors.18 However,
local hypoxia, inflammation and impaired perfusion can act as triggering events, shifting
the balance towards a more pro-angiogenic state.20
Table 1.1. Key molecules that regulate pro- and anti-angiogenic response.18
Pro-angiogenic molecules

Anti-angiogenic molecules

Vascular endothelial growth factor
(VEGF) family
Fibroblast growth factor (FGF) family
Angiopoietin-1 (Ang-1)
Hepatocyte growth factor (HGF)
Platelet-derived growth factor (PDGF)
Matrix metalloproteinases (MMPs)

Angiostatin (plasminogen fragment)
Endostatin (collagen XVIII fragment)
Angiopoietin-2 (Ang-2)
Thrombospondin-1, -2 (TSP-1, -2)
Interferon-α, -β, -! (INF-α, -β, -!)
Tissue inhibitor of metalloproteinases
(TIMPs)
3

During ischemic injury, EC transcriptional responses are mediated by hypoxia-inducible
factors (HIFs) that regulate the expression of pro-angiogenic, metabolic and cell cycle
genes.20 Under high oxygen tension, prolyl hydroxylase (PHD) enzymes mark hypoxia
inducible factor-1α (HIF-1α) for degradation through hydroxylation of 2 proline residues
in its oxidation-dependent degradation domain (ODDD).20 However, under hypoxic (<5%
O2) conditions, the activity of PHD enzymes is attenuated due to limited O2 and cofactor
2-oxoglutarate required for the enzymatic functions.20,21 As a result, HIF-1α is stabilized
and dimerizes with hypoxia inducible factor-1β (HIF-1β)/aryl hydrocarbon receptor
translocator (Arnt).20 The entire complex translocates to the nucleus where it binds to
hypoxia response element (HRE) and upregulates the transcription of over 60 known
genes that influence EC proliferation, migration, and vascular growth.20
Following the transcriptional changes mediated by HIF-1α, stromal cells within the
injured tissues also secrete pro-angiogenic factors such as VEGF and FGF that activate
cognate receptors on nearby ECs.22 Initially, ECs are destabilized by the disruption of
cell-cell contacts through VEGF-mediated dissociation of vascular endothelial (VE)cadherin and Ang-2/Tie-2 interactions with neighbouring mural cells.23 In addition,
VEGF activates ECs to form tip cells, which then guide the developing capillary sprout
through the extracellular matrix (ECM).24 While the tip cell does not divide, the
endothelial stalk cells that follow the migrational front undergo rapid proliferation
stimulated by VEGF, FGF, HGF and transforming growth factor-α (TGF-α) to form a
lumen.23,24 The tip cell guides the migration of the developing sprout along a gradient of
soluble and matrix-bound VEGF.25 MMPs secreted by proliferating ECs mediate the
remodeling of the ECM to facilitate the new vessel growth.26 Cell-cell linkages between
nascent ECs are facilitated by the upregulation of adhesion molecules, including plateletderived endothelial cell adhesion molecule (PECAM or CD31).16,23 Stabilization of the
growing vessel occurs through inhibition of EC proliferation by transforming growth
factor-β (TGF-β), and upregulation of VE-cadherin strengthens the junctions between
ECs.27 Lastly, PDGF facilitates the recruitment and proliferation of tissue-resident
pericytes and vascular smooth muscle cells (SMCs) in order to support the new vessel
through envelopment and matrix deposition, while Ang-1/Tie-2 mediates vascular

4

permeability.16,28 The newly formed capillaries, ~5-20 μm in diameter, fuse with existing
vascular beds and blood flow commences.16

1.2.2

Vasculogenesis

Vasculogenesis is the de novo formation of blood vessels from EC precursor cells, or
angioblasts.29 Until recently vasculogenesis was thought to occur only during embryonic
development.29 However, in 1999, Asahara and Insner reported the existence of
circulating human bone marrow (BM)-derived endothelial precursor cells (EPCs) that
contribute to post-natal vessel formation.30 Post-natal vasculogenesis involves the homing
of circulating EPCs to sites of ischemic injury, and the formation of new vessel networks
through inosculation within advancing or regressing vessel networks.31,32 Growth factors
and chemokines generated as a result of local cellular hypoxia, including VEGF, stromal
cell-derived factor-1 (SDF-1), granulocyte/macrophage colony stimulating factor (GMCSF) and interleukin-8 (IL-8), recruit circulating EPCs to the site of ischemic injury to
facilitate microvascular repair.33 While the role of circulating or vessel-derived EPCs is
not completely understood, early studies suggested that these cells differentiate into
mature ECs and contribute to capillary formation.33,34 However, more recent evidence
suggests that EPCs also promote the proliferation, migration and survival of existing ECs
and pericytes via paracrine mechanisms.35,36

1.2.3

Arteriogenesis

Under normal physiological conditions, pre-existing collateral arteries run parallel to the
large conduit artery.26 Arteriogenesis is the process through which an obstruction of the
conduit artery causes the remodeling and maturation of collateral vessels to increase
perfusion in the distal tissues.37 Initially, elevation of the pressure gradient due to the
vascular obstruction increases the rate of blood flow in the collateral vessels, which
augments the fluid shear stress on the vessel walls.38 This mechano-stimulus alters the
state of the endothelium, causing the activation of endothelial nitric oxide synthase
(eNOS) and subsequent vasodilation of the collateral arterioles.38 Mechanical
deformation of the ECs also enhances mechanoreceptor-dependent transcription of
several adhesion molecules and chemokines, including monocyte chemoattractant
5

protein-1 (MCP-1), SDF-1 and GM-CSF.26,38 Attracted by these molecules, circulating
monocytes migrate to the affected area, adhere to the endothelium, and migrate into the
sub-endothelial space, where they differentiate into macrophages.26,32 In particular, a
transformation towards the M2 macrophage phenotype has been shown to support
collateral vessel formation through the production of supportive growth factors and
cytokines, including VEGF, FGF, and HGF, as well as enzymes such as MMPs.39,40 The
secreted molecules work in concert to cause rapid proliferation of the ECs and vascular
SMCs required for collateral artery enlargement.26 Ultimately, arteriogenesis can result in
the rapid enlargement of the collateral artery diameter up to 20× its original size in an
effort to reduce vascular resistance and restore downstream perfusion.38

1.3 Strategies for Revascularization of Ischemic Limb
Alternative treatments are extremely limited for patients with diffuse PAD or CLI that do
not qualify for surgical revascularization or endovascular procedures. In vivo
compensatory responses to ischemic injury are compromised in patients with PAD,
especially those involved with microvascular remodeling and maturation of collateral
vessels.32 Moreover, the number of circulating EPCs are attenuated in these patients,
likely due to the adverse effects of associated cardiovascular risk factors and comorbidities, such as hyperglycemia and hyperlipidemia.41 Therefore, intrinsic repair
mechanisms become insufficient to overcome the burden of disease, demanding the need
for new strategies to augment revascularization.
As a result, the last 2 decades have seen extensive pre-clinical and clinical research into
the development of new therapeutic interventions to promote vascular regeneration in
patients with PAD. These approaches have primarily focused on the delivery of proangiogenic growth factors through gene therapy approaches or controlled release
strategies, and cell-based therapies to enhance blood flow to the ischemic regions.
Although there has been some success in pre-clinical and clinical trials, several hurdles
remain that limit efficacy and delay widespread use of these alternative therapies.
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1.3.1

Gene Therapy Approaches for PAD

The identification of pro-angiogenic growth factors in the 1980s, such as VEGF and
FGF, led to their investigation in pre-clinical models of PAD to enhance angiogenesis
and support functional improvement in ischemic limbs.26 Due to the short half-life
(minutes) and pleiotropic effects of growth factors, a large number of pre-clinical and
clinical trials have focused on utilizing gene therapy to provide a method for the
sustained release of pro-regenerative factors.26 Gene transfer using plasmids or viral
vectors, such as adenovirus or lentivirus, have served as a method for the localized or
systemic delivery of specific pro-angiogenic factors to induce vascular regeneration in
ischemic tissues.26
In terms of pre-clinical testing, while other in vivo models are emerging, inducing murine
hindlimb ischemia through the ligation of the superficial femoral artery is the most
frequently used model of CLI to date.42 Using these models, gene therapy approaches
have been utilized to stimulate angiogenesis and reperfusion by inducing the expression
of various pro-angiogenic cytokines, including VEGF, FGF-2 and PDGF, and even the
transcription factor HIF-1α.43–49 For example, intra-arterial delivery of adenovirusmediated gene transfer of VEGF in an ischemic hindlimb rat model improved perfusion
and promoted the recovery of tissue oxygenation in the ischemic limb as compared to
PBS controls over 4 weeks.44 Similarly, another study used a rabbit hindlimb ischemia
model to demonstrate that repeated intramuscular injections of VEGF-encoding plasmids
at day 7 and 21 post-surgery increased capillary density, arteriolar density and reduced
muscle lesions as compared to the empty-plasmid control group over 50 days.45 Dual
gene FGF-2/PDGF-BB plasmid administered intramuscularly into the ischemic hindlimb
in rats also enhanced vessel density and limb perfusion as compared to the control
plasmid group at 4 weeks.46 In addition, mediators of angiogenic function, such as eNOS,
have also been studied in pre-clinical trials using gene therapy.49 For example, Brevetti et
al. reported that adenovirus-mediated transfer of eNOS cDNA via intra-arterial
administration in a rat hindlimb ischemia model increased the size and number of
collateral arteries, enhanced muscle oxygen tension and augmented limb perfusion as
compared to PBS or adenoviral vector controls at 14 days.49
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While gene therapy has shown promise in pre-clinical models, clinical trials have
generated mixed results. In two phase I trials, VEGF-encoding plasmids were injected
intramuscularly into the limbs of CLI patients with severe ulcers and ischemic rest
pain.50,51 Patients showed improvements in ankle brachial index (ABI; a ratio of blood
pressures in the foot), improved distal flow, enhanced wound healing and attenuated rest
pain at 4-8 weeks after treatment. However, several patients developed peripheral edema
in both trials, corresponding temporarily to the rise in VEGF serum levels. In a phase
I/IIa trial, HGF-encoding plasmid was administered intramuscularly in the calf or distal
thigh of patients with PAD, and the treatment was repeated 4 weeks after the initial
injection.52 A 2-month follow-up revealed that the patients had improved ABI, ulcer
healing and pain relief without any side-effects. In a phase II clinical trial, the RAVE
(Regional Angiogenesis with Vascular Endothelial Growth Factor) study assessed the
effects of adenovirus encoding VEGF injected intramuscularly at a low- or high-dose in
patients with IC.53 No differences in peak walking time, onset of claudication and qualityof-life assessment were observed between the placebo and the low- or high-dosage
treatment groups at 12 weeks. Similar trends were observed when a plasmid-expressing
developmental endothelial locus-1 (Del-1) or an adenoviral construct encoding HIF-1α
were administered intramuscularly in patients with IC, as the treatment and placebo
groups showed similar improvements in peak walking time at 3 or 6 months.32,54,55
Furthermore, intramuscular delivery of plasmid-based FGF-1 in CLI patients has also
failed to significantly improve transcutaneous oxygen pressure (TcPO2) or healing of
chronic ulcers as compared to the placebo group at 25 weeks.56 In general, large-scale
clinical trials involving gene therapy have demonstrated limited improvements for
patients with moderate to severe PAD.
A postulated reasons for the poor translation of gene therapy in clinical trials may be the
low DNA transmission efficiency at the targeted ischemic sites after treatment.26 In
addition, vectors such as adenovirus and lentivirus employed in gene therapy may elicit a
local and/or systemic inflammatory response.26 Another potential danger of gene-based
therapy involves vector-mediated insertional mutagenesis, as observed in the Fischer
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Trial where one patient developed lymphoproliferative disorder ~2.5 years after the
retroviral-based treatment.57

1.3.2

Cell-based Therapy Approaches for PAD

With the growing understanding of the roles of progenitor and stem/stromal cells coordinating concurrent post-ischemic angiogenesis, vasculogenesis and arteriogenesis
processes, cell-based therapies have drawn attention as potential treatment options for
patients with PAD.58–60 A variety of cell types have been studied in pre-clinical and
clinical trials, including unselected mononuclear cells and marker-specific hematopoietic
cells selected from bone marrow or peripheral blood. While early evidence suggested that
these cells facilitated vascular regeneration by incorporating directly into the nascent
blood vessels, recent studies have shown that the majority of transplanted cells are found
adjacent to the newly-formed vasculature and provide paracrine signals to support
vascular growth.61–63 As an illustration, Ziegelhoeffer et al. demonstrated via cell tracing
of green fluorescent protein (GFP+)-labeled BM-derived mononuclear cells that
intravenously delivered cells in a murine model of hindlimb ischemia failed to colocalize
with the ECs or SMCs of the nascent vessels.64 Instead, GFP+ cells were localized in the
perivascular space of collateral vessels, with a 3-fold higher expression as compared to
the vessels in the non-ligated control limb. Multiple studies have supported the notion
that

transplanted

hematopoietic

progenitors

or

more

mature

cells

of

the

monocyte/macrophage lineage primarily act as trophic mediators during angiogenesis,
through the secretion of a broad array of growth factors and chemokines in a temporally
and spatially controlled manner.63,65 Therefore, cell-based strategies may provide a
suitable means for continuous delivery of pro-angiogenic factors over an extended period
at the target site to facilitate vascular regeneration.

1.3.2.1

Strategies Using Unselected Mononuclear Cells

Mononuclear cells (MNCs), harvested from bone marrow (BM-MNCs) or peripheral
blood (PB-MNCs), are comprised of a highly heterogeneous mix of both primitive
progenitors and mature hematopoietic cells (90%), and a smaller component of nonhematopoietic cells including rare EPCs and stromal cells.66,67 In pre-clinical testing,
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intramuscular injection of autologous BM-MNCs enhanced collateral vessel and capillary
density, and improved perfusion in a rabbit hindlimb ischemia model at 4 weeks as
compared to the BM-fibroblast transplanted groups or saline-injected controls.68 The first
randomized, controlled trial for the treatment of ischemic limbs using the MNC
population was the TACT (Therapeutic Angiogenesis using Cell Transplantation) study,
in which patients with severe limb ischemia received intramuscular injections of
autologous BM-MNCs in the affected limb.69 The study reported improved rest pain,
TcPO2, ABI and pain-free walking as compared to the saline-injected control group at 6
months. A 2-year follow-up to the study added that patients injected with BM-MNC had
improved walking time/distance and ulcer healing.70 Considering that cell collection from
the blood offers faster recovery and eliminates the need for anesthesia as compared to
multiple bone marrow aspirations, PB-MNCs have been investigated as a cell source for
pro-regenerative therapy to treat ischemic limbs.32 For example, Ozturk et al.
administered autologous PB-MNCs intramuscularly in the affected limbs of diabetic
patients with CLI.71 At 12-weeks, patients demonstrated reduced pain and showed
improvements in TcPO2, ABI, walking distance and ulcer healing as compared to the
baseline and placebo group.

1.3.2.2

Strategies Using Selected Mononuclear Cells

The discovery of circulating EPCs by Asahara et al.30 showed that a subpopulation of
MNCs, which can be isolated based on surface markers such as the progenitor marker
CD34, represented a mixture of pro-angiogenic hematopoietic and endothelial cell
lineages that were capable of homing to sites of ischemia to facilitate vascular repair.32,67
In a pre-clinical study, ex vivo expanded human EPCs administered through an
intracardiac injection in a murine hindlimb ischemia model enhanced capillary density
and blood flow in the ischemic limb over 4 weeks as compared to mice injected with
EPC-conditioned media.72 Clinical feasibility of granulocyte colony stimulating factor
(G-CSF)-mobilized CD34+ cells for ischemic limb treatment was evaluated in a phase
I/IIa trial, where cells were harvested by leukapheresis, purified for CD34-expression,
and injected intramuscularly (3 doses: 105, 5×105, 106 cells/kg) into the more severely
ischemic leg of patients with bilateral PAD.73 Although no dose-dependent relationship
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was established after 12 weeks, the treated leg exhibited significant improvements in
ulcer size, pain and walking distance as compared to baseline levels, and exhibited
increased TcPO2 as compared to the untreated leg. Long-term clinical benefits of
autologous G-CSF-mobilized CD34+ cells were also reported by Losordo et al. in the
ACT-34 CLI (Autologous Cell Therapy-34 Critical Limb Ischemia) phase I/II study,
where intramuscular administration of the cells within the ischemic lower limb of patients
with moderate to severe CLI reduced the incidence of amputation in the cell-treated
groups as compared to the control group at 12 months.74
High aldehyde dehydrogenase (ALDH) activity has also been used as a marker to isolate
pro-angiogenic cell populations within the heterogeneous mix of MNCs. ALDH is an
oxidizing enzyme with high expression in primitive hematopoietic progenitors, and BMMNCs can be selected for high ALDH expression in the population that is CD34+,
CD133+, CD13+ and CD117+.75,76 Pre-clinically, human BM-MNCs selected for high
ALDH expression and administered in a murine hindlimb ischemia model through tail
vein injection enhanced perfusion recovery and increased blood vessel density as
compared to PBS-injected and unpurified MNC-treated groups over 21 days.77 A phase I
controlled clinical trial compared the efficacy of unselected BM-MNCs and BM-MNCs
selected for high ALDH activity by injecting autologous cells in the gastrocnemius
muscle of the affected limb in patients with CLI.78 Although both groups demonstrated
significant ABI improvements from baseline at 12 weeks, neither group showed
significant improvement in ischemic ulcers or TcPO2.

1.3.2.3

Current Limitations of Cell-based Therapeutic Approaches

Although direct intramuscular administration of pro-regenerative cells at ischemic sites
has shown some potential in stimulating new blood vessel growth, the application of cellbased interventions in the clinical setting faces several limitations. First, the feasibility of
cell-based therapies is dependent on the abundance and accessibility of the cell source.
Depending on the cell types used, therapy is predicted to require at least 107 to 109 cells
per patient.79 In terms of the cell type used, mononuclear cells are a highly heterogeneous
cell population, with only a small fraction possessing pro-angiogenic capacity.80 For
example, the low frequency (1-2%) of pro-angiogenic CD34+ hematopoietic progenitor
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cells in the mononuclear cell population isolated from bone marrow or umbilical cord
may require clinicians to obtain large sample volumes that may not be practical in all
cases.69,79,81 Significant in vitro expansion of pro-regenerative cells needed for cell-based
therapy may also contribute towards diminished cell function.82 In addition, autologous
cells from patients with chronic diabetes and associated comorbidities have been shown
to have impaired function and reduced survival, thus limiting their pro-angiogenic
effects.83,84
Another major roadblock for cell-therapy is the poor localization, retention and survival
of transplanted cells in the targeted tissues.85,86 While current approaches stimulate
angiogenesis by injecting cell suspensions either intra-arterially or directly into the
ischemic tissue, the viability and desired function of transplanted cells at the targeted
sites remains limited. As an illustration, Collins et al. reported that human BM-MSCs
injected into the ischemic rat heart showed only 9% and 1% cell retention within the
targeted tissue at 24 hours and 5 days post-transplantation, respectively.87 Poor retention
may be explained by cell washout after direct injection, cell migration into the circulation
and peripheral tissues, or cell death due to local hypoxic and inflammatory conditions.85
While the clinical trials with cell-based therapy have been safe, well tolerated, and
showed some beneficial effects, with the exception of the ACT-34 CLI trial, limb salvage
rates were generally not reduced to clinically significant levels and the field still awaits a
successful phase II – III study for CLI.32 As such, there is a critical need to select potent
pro-angiogenic cell populations and design cell delivery modalities that improve cell
survival, retention and paracrine function post-transplantation to better stimulate vascular
regeneration and functional recovery in ischemic tissues.

1.4 Mesenchymal Stem/Stromal Cells for Cell-based
Angiogenic Therapies
Mesenchymal stem/stromal cells (MSCs) are fibroblast-like plastic adherent cells that can
be derived from a variety of tissues, including bone marrow, adipose tissue and skeletal
muscle, and hold the potential to circumvent some of the practical limitations associated
with cell-based therapies for PAD.88 MSCs are efficiently expanded in culture and retain
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the capacity to differentiate into multiple different cell types associated with the
mesodermal lineage, including adipocytes, osteocytes, chondrocytes and myocytes.89
While the regulation of paracrine activity in MSCs is not completely understood, studies
have shown that these cells migrate to sites of ischemic injury from their perivascular
niche, and secrete bioactive factors that can stimulate angiogenesis, limit apoptosis,
modulate inflammation, and enhance endogenous cell recruitment to the site of injury.90,91
In addition, MSCs have been shown to be resilient to apoptosis under serum-starvation or
hypoxic conditions, making them a promising source for cell-based therapies targeted for
ischemic tissues.92 MSCs can be used for autologous or allogeneic therapeutic
applications due to their ability to evade immune-surveillance resulting from the low
expression of the major histocompatibility complex II antigen.93,94 In addition to their proangiogenic paracrine capacity, MSCs demonstrate immuno-modulating effects at
ischemic sites via the suppression of inflammatory cytokine production and by
attenuating T-cell activation, proliferation, and migration.94
Due to their pro-regenerative properties, MSCs have also been pursued as a potential
candidate for cell-based therapies.95 In a pre-clinical trial, autologous BM-MSCs injected
intramuscularly in a femoral artery ligation (FAL)-induced rabbit hindlimb ischemia
model significantly increased limb perfusion and capillary/muscle fiber density in the
treated limbs as compared to saline-injected control limbs at 28 days.96 Similarly, human
placental-derived MSCs cultured under hypoxic conditions (2% O2) significantly
improved microvessel density, blood perfusion and physiological status (limb salvage
and foot necrosis) in the treated limb as compared to PBS controls over 28 days
following intramuscular injection in a murine hindlimb ischemia model.97
In a randomized controlled clinical trial, either BM-MNCs or BM-MSCs were injected
intramuscularly into the lower limbs of diabetic patients with CLI.98 While both groups
significantly improved pain-free walking time at 6 months as compared to saline injected
controls, the BM-MSC treated group showed significantly greater collateral blood vessel
scores and faster ulcer healing time (8 vs. 12 weeks) relative to the BM-MNC group,
suggesting the potential benefits of MSCs over unselected BM-MNCs. More recently,
human BM-MSCs isolated from healthy donors were expanded in vitro and injected into
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the gastrocnemius muscle of the ischemic lower limb of patients with CLI.99 At 24
weeks, patients demonstrated significantly higher ABI and reduced pain as compared to
baseline levels and the placebo group. Given these positive outcomes, MSCs provide a
clinically-applicable pro-regenerative cell population for future cell-based therapy.

1.4.1

Adipose-derived Stem/Stromal Cells (ASCs)

Adipose-derived stem/stromal cells (ASCs) have gained interest as an attractive MSC
cell-type for regenerative therapies due to their relative abundance, accessibility, and
secretory functions.93,100 ASCs are derived from adipose tissue and have promising
characteristics for applications in therapeutic angiogenesis.93 ASCs actively secrete
multiple pro-angiogenic factors and cytokines, including VEGF, FGF-2, HGF, PDGF and
TGF-β, that are involved in the process of vascular regeneration.101 ASCs can also be
readily expanded in culture, and have been shown to establish a regenerative milieu in
vivo through paracrine mechanisms.93,102–104
In addition to their pro-angiogenic stimulatory potential, ASCs offer practical advantages
for their clinical applicability in cell-based therapies. Although MSCs can be sourced
from the patient’s own bone marrow, the retrieval process is invasive, painful and may
not be ideal for individuals with adverse vascular conditions such as CLI. In contrast,
adipose tissue can be harvested via minimally-invasive liposuction techniques under local
anesthesia, with minor morbidity.93 In addition, compared to the MSC frequency of
1:50,000–1:1,000,000 in bone marrow, ASC frequency in human adipose tissue ranges
between 1:30–1:100 per total nucleated cells, and therefore requires less tissue to
generate significant numbers of ASCs for cell-based therapies.85,100,105,106 Furthermore, a
limited volume of bone marrow can be safely harvested from each donor, which could
necessitate significant in vitro expansion of BM-MSCs for cell-based therapies. Adipose
tissue however, offers a source of MSCs in high abundance with large proliferative
potential, thereby enhancing the feasibility of safely harvesting the required volumes of
adipose tissue and minimizing culture times for ex vivo expansion.79,88
In pre-clinical testing, intramuscular injection of human ASCs into the ischemic limb of
nude mice with FAL-induced hindlimb ischemia significantly enhanced vascular density
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and blood flow in the treated limb as compared to the saline-injected control limb at 14
days.107 Similarly, ASCs isolated from murine inguinal fat pads and transplanted
intramuscularly into the ischemic hindlimb of mice enhanced capillary density within the
thigh adductor muscles and improved blood flow as compared to saline-injected controls
at 4 weeks.108 The first phase I clinical trial utilizing autologous MSCs isolated from
abdominal fat of CLI patients, ACellDream (Adipose Cell Derived Endothelial
Regenerative Endothelial Angiogenic Medicine), demonstrated that intramuscular
administration of the cells in the ischemic limb improved rest pain, TcPO2 and woundhealing response at 24 weeks.109 Intramuscular administration of autologous adiposederived MSCs around the edges of chronic ulcers in PAD patients significantly reduced
the depth and diameter of the wounds over 90 days, while also reducing the woundassociated pain.110 Therefore, ASCs have demonstrated pro-regenerative potential in cellbased therapies.

1.4.2

Immunophenotype of ASCs

The primary stromal vascular fraction (SVF) isolated after adipose tissue digestion
consists of a heterogeneous cell population, including ASCs, vascular endothelial and
smooth

muscle

cells,

pre-adipocytes,

fibroblasts,

erythroblasts,

pericytes

and

hematopoietic cells.111 This heterogeneity is reduced by using expansion conditions that
select for plastic-adherent stromal cells. ASC characterization has been defined under the
guidelines of the International Society for Cellular Therapy (ISCT) and the International
Federation for Adipose Therapeutics and Science (IFATS).112 To adhere to the ASC
characterization criteria, ASCs must: (1) maintain plastic adherence in cell culture, (2)
express a standardized immunophenotypic profile, and (3) maintain tri-lineage
differentiation capacity along the adipogenic, osteogenic, and chondrogenic lineages.
According to the ISCT and IFATS, ASCs must show >80% expression of defined
stromal cell markers (CD90, CD44, CD29, CD73 and CD105) and <2% expression of
hematopoietic (CD45) and endothelial (CD31) cell specific markers.112 ASCs have been
shown to express a fairly robust immunophenotypic profile as summarized in Table
1.2.93,112–114 As demonstrated by Mitchell et al., successive passaging of ASCs may alter
expression of certain cell surface markers.100 For example, while the surface marker
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expression of CD34 and CD146 were ~60% and 21% in the initial SVF, the expression of
each marker declined to ~2% by passage 3 for human ASCs.100
Table 1.2. Immunophenotypic profile of ASCs.93,112–114
Marker type

Category

Positive
(>80%)

Adhesion
molecules

Antigen

CD29 (integrin β1)
CD105 (endoglin)
CD50 (intercellular adhesion molecule 1)
CD54 (intercellular adhesion molecule 3)
CD166 (activated lymphocyte cell adhesion
molecule)
Receptor molecules CD44 (hyaluronic acid receptor)
CD71 (transferrin receptor)
Surface enzymes
CD73 (ecto 5’nucleotidase)
CD13 (aminopeptidase)
CD10 (neutral endopeptidase)
Surface
CD90 (Thy-1)
glycoproteins
CD147 (neurothelin)
CD146 (melanoma cell adhesion molecule)*
CD34 (progenitor associated marker)*
Negative
Adhesion
CD31 (platelet endothelial cell adhesion
(<2%)
molecules
molecule)
CD106 (vascular cell adhesion molecule)
Receptor molecules CD45 (leukocyte common antigen)
CD3 (T-cell co-receptor)
Surface
CD133 (hematopoietic and endothelial
glycoprotein
progenitor marker)
100
*Variable levels of expression.

1.4.3

Influence of Hypoxia on ASCs

As PAD progresses, the lack of oxygenated blood flow to the distal limb creates a
hypoxic microenvironment, resulting in cell apoptosis and subsequent necrosis of the
affected tissues.115 A TcPO2 of <20 mm Hg (<2% O2) in the lower extremity is correlated
with impaired healing, requiring patients to undergo revascularization procedures or
amputation to treat the severe conditions.115 Therefore, the efficacy of cell-based therapy
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for PAD relies on the transplanted cells being able to survive and function in
microenvironments with low oxygen tension.
Under hypoxic conditions, ASCs have been shown to upregulate expression of several
pro-angiogenic genes, including VEGF, FGF-2, HGF, Ang-1, PDGF and SDF-1, and
cytokines such as interleukin-10 (IL10) and interleukin-8 (IL-8).116–118 The elevated
expression of these pro-angiogenic molecules is achieved through the activity of HIF-1α
under low oxygen tension (<5% O2).119–121 One study showed that the conditioned
medium obtained from human ASCs cultured under hypoxic conditions (1% O2) can
improve endothelial cell growth and reduce apoptosis.122 In addition, hypoxic preconditioning of human ASCs enhances their ability to bind to vascular cell adhesion
molecule-1 (VCAM-1) and endothelial intercellular adhesion molecule-1 (ICAM-1),
suggesting the potential for augmented attachment to endothelial cells in ischemic
regions.123 Hypoxic conditions (1% O2) have also been shown to enhance human ASC
proliferation in vitro by >1.5-fold as compared to ASCs cultured under 20% O2 over 7
days.124 Collectively, ASCs are generally resilient to hypoxic conditions in terms of
survival and function, thus providing support for their use in cell-based therapies to
promote angiogenesis at ischemic sites.

1.5 Biomaterials for Scaffold-based Cell Delivery
As discussed earlier, poor retention and survival of transplanted cells are major
limitations identified in previous studies of cell-based therapies for PAD.85,125,126 As a
result, scaffold-based cell delivery strategy has emerged to circumvent cell loss by
providing anchorage for the transplanted cells while promoting cell viability and function
at ischemic sites.127 Scaffolds can be developed to have similar porosity and
nanostructure as the native ECM to support in vivo engraftment, and can also be modified
with cell-signaling moieties to facilitate cell-cell and cell-ECM interactions.127 Therefore,
in-depth analysis of biomaterial design is required to develop promising scaffolds for
cell-based therapy.
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1.5.1

Scaffold Design Requirements

Designing a cell-delivery scaffold for enhancing transplanted ASC survival within the
context of PAD requires careful consideration of material requirements. Ideally, the
scaffold should retain viable cells at the target site over the course of tissue regeneration.
In addition, the scaffold should provide anchorage for encapsulated cells to support cell
function by promoting the sustained delivery of pro-regenerative paracrine factors into
the ischemic region.85 To facilitate the intended role of ASCs as trophic mediators, the
scaffold must allow for easy diffusion of nutrients and factors between encapsulated
ASCs and the surrounding microenvironment.128 Furthermore, the mechanical properties
of the scaffold should align with those of the surrounding tissues at the target site to
minimize physical irritation, prevent inflammation and facilitate integration of the
scaffold after delivery.129 For instance, the Young’s modulus of the medial gastrocnemius
in the limb of resting human subjects is ~16 kPa.130 Accordingly, a scaffold with similar
mechanical properties would promote better integration within the target muscle in
patients with PAD. In addition, the scaffold should be pliable, durable, and able to resist
repeated mechanical deformation during muscle contractions with minimal risk of
fracture.129 Lastly, the transplanted scaffold should also undergo biodegradation at a slow
rate to retain the transplanted cells during the course of the therapy, and break down in a
manner that does not interfere with ongoing vascular remodeling processes.16
In general, two methods of scaffold delivery have been investigated in the context of proangiogenic cell therapies. One option is the surgical implantation of cell-seeded preformed scaffolds. Although pre-formed scaffolds allow for greater control over scaffold
shape, this approach requires invasive surgical techniques for implantation at target
sites.85 A less invasive approach is to deliver a bolus of cells suspended in an aqueous
polymer precursor solution (pre-polymer) as an injectable substrate that subsequently
cross-links in situ to form a robust hydrogel scaffold, effectively encapsulating the
delivered cells.16,85 Injectable delivery offers several advantages for PAD treatment
including minimally-invasive cell delivery using a small gauze needle, shorter procedure
time, and minimal damage to the already compromised ischemic region.85 Due to these
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benefits, our collaborative team has focused on investigating the use of cross-linkable
polymers as an in situ-gelling cell delivery scaffold.

1.5.1.1

Hydrogels

Hydrogels are water-swollen polymer networks that are physically or chemically crosslinked.16 They can be prepared from biocompatible and biodegradable polymers that
provide a supportive microenvironment for cell-delivery applications.131 Since hydrogels
are inherently well hydrated, they allow for easy diffusion of gasses, nutrients, metabolic
products and bioactive molecules from within the scaffold to the surrounding tissues.131
Additionally, the mechanical properties of the hydrogel can be controlled through crosslinking density, electrostatic interactions of the polymer chains, and the degree of
swelling to tailor their use towards the in vivo environment of the target tissue.16
Generally, the pre-polymer solution is combined with the cells of interest in an aqueous
medium and injected into the target site, where it subsequently cross-links to form a
scaffold in situ.
Several natural and synthetic polymers have been investigated as cell delivery vehicles.
Scaffolds comprised of synthetic polymers, including poly(ethylene glycol), poly(lactic
acid), poly(N-isopropylacrylamide) and poly(vinyl alcohol), offer several advantages
such as batch-to-batch consistency, amenability to chemical functionalization, and
precise control over mechanical and degradation properties.85 However, they lack the
innate bioactivity of natural materials that can better support cell adhesion, viability,
migration, and differentiation.85,132 Furthermore, acidic degradation products of synthetic
polymers such as poly(lactic acid) can be cytotoxic and may trigger inflammatory
responses.133,134 Concerns regarding in vivo excretion also exist with synthetic scaffolds.
For example, poly(N-isopropylacrylamide) may accumulate in the liver and spleen to a
significant extent within 48 h of intravenous administration, regardless of its molecular
weight.135 To circumvent the limitations of synthetic materials, several major classes of
naturally-derived or semi-synthetic polymers have been studied within the context of
ischemic conditions, as described in detail in section 1.5.2.
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1.5.1.2

Cross-linking Strategy

An injectable cell-delivery scaffold requires a cross-linking mechanism that allows for
cell loading in the aqueous phase, but then forms a cell-encapsulated matrix following
injection. An efficient mechanism should initiate gelation in a triggered or controlled
fashion in order to prevent premature or delayed cross-linking, and the cross-linking
should not initiate an immunogenic response.85 Most importantly, the cross-linking
mechanism should be cytocompatible to encapsulated cells, as well as the surrounding
host tissues.85
Although several physical and chemical methods have been investigated to facilitate
cross-linking of hydrogel polymer networks, there are a limited number of clinicallyapplicable cross-linking strategies appropriate for cell encapsulation. For instance,
glutaraldehyde cross-linking of hydroxylated polymers requires methanol, low pH and
high temperatures.136,137 These conditions, along with the inherent reactivity of
glutaraldehyde to amines, amides and thiol groups in proteins, would render this
approach cytotoxic for the encapsulated cells and could further damage the ischemic
tissues.138
Hydrophilic polymers including hyaluronic acid (HA), chitosan, and chondroitin sulfate
can be modified to undergo chemical cross-linking via radically-initiated methacrylate or
acrylate polymerization.129,139 The methacrylate and acrylate groups contain highly
reactive

double

bonds

that

propagate

cross-linking

through

free-radical

polymerization.140,141 This cross-linking approach can offer flexibility in terms of the pH,
osmolarity, and temperature conditions, and may present an attractive strategy for in situ
gelation of polymer scaffolds. For instance, low-intensity UV cross-linking of
methacrylated glycol chitosan in the presence of the photo-initiator Irgacure 2959 has
been shown to generate hydrogels with high cross-linking efficiency.140 Although UV
cross-linking of methacrylated polymers is effective in vitro, direct access of a UV light
at the site of delivery increases invasiveness of implantation and limits clinical
applicability. Alternatively, a chemical initiator to catalyze free-radical polymerization
using

ammonium

persulfate

(APS)
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and

the

accelerator

N,N,N’N’-

tetramethylethylenediamine (TEMED) offers an attractive cross-linking approach. This
system of redox initiators generates free radical species, which subsequently facilitate
methacrylate cross-linking at 37ºC.142,143 The efficacy of this thermally-sensitive crosslinking approach has been previously shown in vitro and in vivo.129,144 For example, one
study used 25 mM APS/TEMED to encapsulate rat BM-MSCs in diacrylate-modified
oligo[poly(ethelene glycol) fumarate] hydrogels at 37ºC.144 Over a 28-day culture period,
the encapsulated cells were able to maintain viability and differentiate in the presence of
osteogenic supplements. Therefore, APS/TEMED-facilitated free-radical polymerization
of methacrylate- or acrylate-functionalized scaffolds offers a promising cross-linking
strategy for in situ gelation and cell encapsulation.

1.5.1.3

Cell-adhesive Peptide Ligand Functionalization

With increasing understanding of the important roles of cell-ECM interactions in
mediating cell function, there is great interest in the development of novel biomaterials
that mimic the native tissue microenvironment. While cross-linking allows for the
manipulation of the mechanical properties of the scaffolds, biomaterials can be
functionalized with bioactive moieties to further direct cell function. Some studies have
explored the incorporation of full-length ECM proteins such as collagen, fibronectin,
vitronectin and laminin. Alternatively, polymers can be modified with small bioactive
peptide ligands derived from these common ECM proteins, such as the integrin-binding
RGD, IKVAV or YIGSR sequences.145,146
These ECM-derived peptide ligands bind to integrins—a diverse class of α/β
heterodimeric transmembrane cell-adhesion receptors (Figure 1.1).147 While each α/βheterodimer has its own ligand binding specificity, many integrins bind more than one
peptide ligand.148,149 Integrin-mediated binding of cells with ECM-derived peptide
ligands has been shown to mediate a variety of cell responses including attachment,
growth and motility.150–152 Although the specific mechanisms are still being elucidated,
integrin engagement facilitates transduction pathways through phosphorylation of
intracellular proteins and second messenger signaling to promote cell adhesion, survival,
proliferation and migration (Figure 1.1).153,154 Individual cells can also vary their
adhesive and migratory properties by selective expression of integrins with varying α/β
21

subunit composition.149 Importantly, cells detached from their ECM have been shown to
undergo apoptosis in an integrin-mediated pattern known as anoikis.155 As an illustration,
fibronectin or vitronectin binding via integrins α5β1 and αvβ3 in hamster ovary cells
decreased the activity of apoptosis-inducing caspase-3 protein, and enhanced the
expression of B-cell lymphoma-2 (Bcl-2), a regulatory protein that inhibits apoptosis.156
In general, the functionalization of scaffolds with integrin-binding cell-adhesive peptides
is of interest in the field to promote long-term cell survival, retention and support proregenerative cell functions.

Figure 1.1. Schematic representation of integrin structure. Integrins are heterodimeric receptors
consisting of non-covalently bound α and β subunits. Both α and β subunits have an extracellular
domain that binds to peptide ligands (e.g. RGD, IKVAV, etc.), and a short cytoplasmic tail that
interacts with cytoskeletal elements. Integrin engagement facilitates downstream intracellular
signaling, influencing various transduction pathways and mediating multiple cell functions. Image
adapted from Millard et al.157 FAK: focal adhesion kinase; PI3K: phosphoinositide 3-kinase; Akt:
protein kinase B; MAPK: mitogen-activated protein kinase; ERK: extracellular signal-regulated
kinase.
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1.5.1.3.1

Arginine-Glycine-Aspartic Acid (RGD) Motif

The tri-peptide arginine-glycine-aspartic acid motif, or RGD, is an integrin-binding
sequence derived from fibronectin and collagen.158 RGD is a well characterized adhesion
motif that was originally shown to facilitate binding through the α1β1 complex.158
Currently, as many as 12 out of the 20 known integrins have been shown to recognize the
RGD sequence, including αvβ3 and α5β1.158 Since RGD is found in many cell adhesion
proteins, it has been used to promote cell attachment to various biomaterials and can be
recognized by many cell types, including MSCs.159–161 For example, rat BM-MSCs
seeded within RGD-modified oligo[poly(ethylene glycol) fumarate] hydrogels have
demonstrated improved cell adhesion and spreading.162 More recently, mouse BM-MSCs
encapsulated within HA hydrogels demonstrated enhanced cell attachment, spreading and
β1 integrin expression in a dose-dependent manner when presented with RGD motifs.163
In a comparative study, RGD-modified poly(ethylene glycol) (PEG) hydrogels
demonstrated improved viability of seeded human BM-MSCs as compared to unmodified
controls over 7 days, while this effect was less pronounced in IKVAV-modified
hydrogels.164

1.5.1.3.2

Isoleucine-Lysine-Valine-Alanine-Valine (IKVAV) Motif

Laminin is a basement membrane glycoprotein with diverse biological roles.165 The
isoleucine-lysine-valine-alanine-valine motif, or IKVAV, derived from the laminin-α1
chain has been suggested as the sequence that facilitates cell adhesion, spreading and
outgrowth.165 Interestingly, rat pre-adipocytes demonstrated enhanced α1β1-mediated
adherence on laminin-1 treated ECM substrates as compared to fibronectin and collagen
treated groups.166 Immobilization of IKVAV motifs on collagen type I hydrogels has
also been shown to stimulate migration, adhesion, and capillary network formation in
vascular endothelial cells.167 Further, human neural stem cells encapsulated within silk
fibroin-based hydrogels covalently modified with IKVAV peptides enhanced cell
viability and differentiation capacity relative to non-peptide modified controls.168 In
addition, supplementation of IKVAV peptide in cell culture media has been shown to
induce proliferation of human BM-MSCs in a dose-dependent manner, mediated through
the activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) and protein
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kinase B (Akt) signaling pathways, and through augmented cell cycle progression into S
phase.169 Taken together, the pro-survival effects of the integrin-binding RGD and
IKVAV peptide ligands have been well documented, providing a rationale for
incorporating these motifs within cell-delivery scaffolds.

1.5.2

Polymers for Hydrogel Scaffold

1.5.2.1

Chitosan

Chitosan is the deacetylated form of the linear polysaccharide chitin—a component of
crustacean exoskeletons—and consists of random (1-4)-linked β-D-glucosamine and Nacetyl-D-glucosamine monomers (Figure 1.2A).85 Chitosan is an attractive material for
cell-delivery applications due to its cytocompatible, biodegradable, hemostatic,
antimicrobial and wound healing properties.170–172 Chitosan has also been suggested to
induce neovascularization in ischemic tissues due to its innate pro-angiogenic nature.173,174
The

electrostatic

interactions

of

chitosan

with

glycosaminoglycans

(GAGs),

proteoglycans and other negatively charged species in the body have the potential benefit
of sequestering pro-regenerative growth factors and facilitating scaffold integration with
the native tissues.175 Chitosan can undergo degradation in vivo through the action of
lysozymes

via

hydrolysis,

generating

biocompatible

oligosaccharides

and

glucosamines.170,176 In addition, components of chitosan have been shown to improve cell
viability by protecting the cells from reactive oxygen species (ROS), such as H2O2,
generated in the ischemic tissues.174 In addition, chitosan-based hydrogels have been
previously explored to promote cell retention in vivo. For example, a temperaturesensitive chitosan hydrogel was used to encapsulate and deliver rat ASCs in a rat MI
model.174 The findings indicated that a higher retention of transplanted cells was noted
with hydrogel-based cell delivery as compared to PBS controls over 28 days.
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Figure 1.2. Chemical structure of chitosan and its derivatives. (A) Chitosan, composed of
(1-4)-linked β-D-glucosamine and N-acetyl-D-glucosamine monomers, (B) glycol chitosan, and (C)
N-methacrylate glycol chitosan. Images adapted form Russo et al.85

Although chitosan demonstrates limited solubility in aqueous environments at
physiological pH, its glycosylated form known as glycol chitosan (GC) (Figure 1.2B) is
soluble between pH 2-12.177 Furthermore, GC can be functionalized with methacrylate
groups via a ring opening reaction with glycidyl methacrylate (GMA) to form Nmethacrylate glycol chitosan (MGC) (Figure 1.2C).140 To initiate cell encapsulation, the
MGC pre-polymer and cell suspension can be mixed with APS and TEMED at room
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temperature. Although the formation of radical species begins immediately, the slow rate
of this reaction at room temperature allows for easy handling of the material. Upon
injection or incubation at 37ºC, the elevated temperature increases the rate of the initiator
decomposition and free-radical formation. The increased molecular kinetics at higher
temperatures also enhances the mobility of the polymer chains, resulting in cross-linking
of the methacrylate groups and rapid gelation of the MGC to facilitate cell
encapsulation.129,144,178 Therefore, the pro-regenerative and cytocompatible nature of
chitosan, combined with the practical advantages offered by the MGC polymer, lend
support for its use as a bioscaffold in cell-based delivery, as investigated in this thesis.

1.5.2.2

Alginate

Derived from brown seaweed and algae, alginate is a natural anionic polysaccharide
composed of (1-4)-linked β-D-mannuronic acid (M unit) and α-L-guluronic acid (G
unit).85 Addition of divalent cations such as Ca2+ and Ba2+ causes the G unit blocks on
adjacent chains to bind and form an ionic cross-linked network.85 Silva et al.
demonstrated that the combination of VEGF and human umbilical cord blood-derived
EPCs pre-seeded on implantable peptide-modified alginate scaffolds was able to improve
vessel density, restore perfusion and salvage ischemic limbs in a murine model of
hindlimb ischemia.179 In addition, alginate has been studied as an injectable cell delivery
vehicle in pre-clinical models of MI, where the increased post-MI concentration of
calcium ions facilitates the physical cross-linking process.180,181 As such, the gelation and
degradation of alginate hydrogels is dependent on the local cation concentration in
ischemic tissues and ion efflux into the surrounding tissues, respectively. This leads to an
uncontrolled cross-linking approach, with degradation products being eliminated by the
kidneys if below the excretion limit of 48 kg/mol.182 Furthermore, the hydrophilic nature
of alginate necessitates grafting of cell-adhesive peptide ligands to promote encapsulated
cell viability, as the unmodified scaffold limits protein adsorption and cellular
attachment.183
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1.5.2.3

Collagen

Being a key component in the ECM, type I collagen derived from bovine or porcine
tissues has been studied as a natural scaffold.85 It is also commercially-available and can
be prepared as an injectable hydrogel by acid-solubilization.184 Collagen can undergo
entropy-driven self-assembly through fibriollogenesis to form a physically cross-linked
hydrogel capable of encapsulating cells upon in vivo injection at neutral pH and
37ºC.184,185 Although collagen-based hydrogels support cell encapsulation and attachment,
the solubilization process causes the hydrogel to lack elements of structural integrity and
organization, including stiffness and elasticity.186 Furthermore, the cross-linking process
is sensitive to in situ variations of pH and salt concentration, resulting in poor control
over gelation and degradation of the scaffold.186 Delivery of radio-labeled MSCs via
collagen hydrogels in a pre-clinical rat model of MI demonstrated that the hydrogel
transiently improved MSC retention as compared to saline-delivered cells at 4 weeks.187
However, the scaffold attenuated long-term survival of encapsulated MSCs by impairing
oxygen and nutrient exchange.

1.5.2.4

Fibrin

Fibrin is a fibrous, non-globular protein that is involved in the coagulation cascades, and
thus contains intrinsic sites for cell binding.85 Fibrin hydrogels are formed when
fibrinogen is cleaved by thrombin, resulting in the rapid aggregation of the insoluble
fibrin peptides that creates a fibril network capable of encapsulating cells.188 Due to the
cross-linking nature of fibrin, the physical properties of the hydrogels, including gelation
kinetics, stiffness and elastic moduli, can be tailored by altering the concentrations of
thrombin

and

fibrinogen.189

Enzymatic

degradation

of

fibrin

produces

non-

immmunogenic amino acid products that may also contribute towards angiogenesis.190
Fibrin has been previously used as a delivery vehicle for MSCs or growth factors in preclinical models of ischemia, and has been shown to promote functional repair in rat MI
models over PBS controls.191 However, fibrin hydrogels have demonstrated poor
mechanical properties in situ.192,193 Furthermore, commercially-available fibrin glues have
failed to show improvement in long-term cell retention and function after injection.194
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1.5.2.5

Hyaluronic Acid

Hyaluronic acid, or HA, is a linear glycosaminoglycan composed of repeating
disaccharide units of (1-4)-linked β-D-glucuronic acid and (1-3)-linked β-N-acetyl-Dglucosamine.85 As a widely distributed component of the ECM in mammalian tissues, HA
is involved in cellular proliferation and differentiation, and has been shown to have proangiogenic effects.195 In a pre-clinical model of murine hindlimb ischemia, delivery of
human umbilical vein endothelial cells (HUVECs) in combination with injectable HA
resulted in prolonged cell retention, survival and cellular engraftment into the
endothelium.196 HA can also be modified to produce a cross-linkable methacrylated HA
(MeHA) that can undergo free-radical mediated polymerization to form a hydrogel.129
Cell-free delivery of MeHA hydrogels has demonstrated potential in promoting the
remodeling of ischemic tissues in a pre-clinical ovine MI model.139 However, the longterm potential of HA as a cell-delivery scaffold is hindered by its rapid enzymatic
degradation in vivo, with unmodified HA degrading into glucuronic acid and Nacetylglucosamine at a rate of 5 g/day.197

1.5.2.6

Matrigel™

Generated by murine tumor cells, Matrigel™ is a commercially-available material
composed of laminin, entactin, collagen IV and other ECM components.85 Previous preclinical research with a rat MI model demonstrated that the delivery of human embryonic
stem cells (ESC)-derived cardiomyocytes in a Matrigel™ scaffold at ischemic sites
resulted in poor cell viability and retention.198 When the study was repeated with a
combination of cells and pro-survival growth factors delivered via the Matrigel™
scaffold, the comprehensive approach led to augmented cell survival and cell retention at
the targeted ischemic site at 4 weeks.198 Despite these promising results, the xenogenic
and tumorogenic origins of Matrigel™ prohibits its widespread translation in clinical
applications.199

1.6 Summary
The rising incidence and limited treatment options for PAD motivate the need for new
minimally-invasive treatment approaches to help stimulate new blood vessel formation
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and tissue regeneration.1 Using an integrative approach combining cell-based therapy
with scaffold-based delivery may improve angiogenesis inducing therapies for PAD and
CLI. ASCs isolated from human adipose tissue offer a promising source for cell-based
therapy due to their accessibility, high proliferative capacity, and paracrine function that
stimulates pro-angiogenic responses and modulates inflammation.93,102–104 To address the
poor survival and retention of transplanted cells, ASCs will be delivered in a thermallysensitive MGC pre-polymer that cross-links into a hydrogel through free radical
polymerization using an APS/TEMED initiator system.142,143 To promote ASC adhesion
and retention within the hydrogel, MGC will be functionalized with integrin-binding
peptide ligands, including RGD found in fibronectin and collagen, or IKVAV derived
from the laminin-α1 chain.145,165 The overarching goals of this thesis were to: (i) assess
the viability and pro-angiogenic capacity of human ASCs encapsulated in the MGC
hydrogels through in vitro and in vivo studies, and (ii) examine the effects of modifying
the MGC with cell-adhesive RGD or IKVAV motifs on encapsulated cell function.
Overall, this project aims to provide fundamental insight into the angiogenic function of
human ASCs within 3-D engineered cellular microenvironments, and represents a critical
next step in the rational design of a cell delivery vehicle for therapeutic angiogenesis.

1.6.1

Hypotheses

The underlying hypotheses for this project were that in situ cross-linking MGC hydrogels
would provide a cell-supportive platform to facilitate human ASC encapsulation and
retention with high cell viability, and that modification of the MGC with peptides
incorporating the integrin-binding RGD or IKVAV sequences would modulate the
angiogenic potential of the delivered ASCs.

1.6.2

Specific Aims

The specific aims of this Master’s project were:
1) To assess the viability of human ASCs encapsulated within (i) MGC, (ii) MGCRGD, and (iii) MGC-IKVAV hydrogels cultured under simulated hypoxic
conditions (2% O2) for up to 14 days.
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2) To assess the expression of angiogenesis-associated genes in human ASCs
encapsulated within (i) MGC, (ii) MGC-RGD, or (iii) MGC-IKVAV hydrogels
and cultured for 7 days under simulated hypoxic conditions (2% O2) relative to 2D tissue culture polystyrene (TCPS) controls.
3) To assess in vivo human ASC retention and markers of angiogenesis in the (i)
MGC, (ii) MGC-RGD, or (iii) MGC-IKVAV hydrogels at 14 days following
subcutaneous implantation in immunocompromised NOD/SCID mice.
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Chapter 2

2

MATERIALS AND METHODS

Unless otherwise specified, all chemical reagents used in this project were purchased
from Sigma-Aldrich Canada Ltd. (Oakville, ON).

2.1 N-Methacrylate Glycol Chitosan (MGC) Hydrogel
2.1.1

MGC Synthesis and Peptide Functionalization

The N-methacrylate glycol chitosan (MGC) was prepared by Stuart Young (PhD
Candidate) in Dr. Brian Amsden’s Lab at Queen’s University following published
protocols.140,141,200
Preparation of MGC: Glycol chitosan (GC, 85% degree of deacetylation; Wako
Chemicals Inc., Virginia, USA) was dissolved in deionized water at 1% (w/v) and filtered
to remove insoluble impurities. The solution was dialyzed using 50 kDa molecular
weight cutoff membrane against distilled water, and then lyophilized to obtain purified
GC. The purified GC was dissolved at 2% w/v in a 0.2 M sodium phosphate buffer at pH
9, and reacted with either a 0.15 or 0.22 molar ratio of glycidyl methacrylate (GMA) to
free amine of GC. The reaction was neutralized with 1.0 M hydrochloric acid, and the
solution was dialyzed using a 12-14 kDa molecular weight cutoff membrane against
distilled water. The resulting MGC solution was lyophilized, yielding a white crystalline
powder.140 The degree of N-methacrylate substitution (DOS) was defined as the number
of grafted methacrylate groups per 100 residues.
Functionalization of MGC with an RGD-containing peptide: The GGGGRGDS peptide
(RGD, 94% purity; CanPeptide Inc., Pointe-Claire, QC) peptide was dissolved at
2% (w/v) in 0.15 M sodium phosphate buffer at pH 5.5. Next, 2.3 molar equivalents of Nacryloxysuccinimide were dissolved in dimethylformamide and added dropwise,
accounting for 10% of the final reaction volume. The reaction was stirred at 4°C, then
diluted by half with distilled water and dialyzed using a 500 Da molecular weight cutoff
membrane against distilled water. The purified solution was lyophilized to obtain N31

terminal acrylated GGGGRGDS (Acr-RGD). MGC with a 5% degree of methacrylation
was dissolved at 0.5% (w/v) in a 0.2 M sodium phosphate buffer at pH 8.5. The AcrRGD was added at a rate of 0.0625 mole per mole of MGC residue, and the solution was
stirred at 37°C. The solution was then dialyzed using a 6-8 kDa molecular weight cutoff
membrane against 0.2 M sodium chloride, and then against distilled water. The purified
solution was lyophilized to obtain MGC functionalized with the GGGGRGDS peptide
(MGC-RGD).141
Functionalization of MGC with an IKVAV-containing peptide: MGC with a 7% degree
of methacrylation was dissolved at 0.5% (w/v) in a 0.2 M sodium phosphate buffer at pH
8.5. The CSRARKQAASIKVAVSADR peptide (IKVAV, 93% purity; CanPeptide Inc.,
Pointe-Claire, QC) was added at a rate of 0.05 mole per mole of MGC residue. A 2-fold
molar equivalent of N-hexylamine was added, and the reaction was stirred at 37°C. The
solution was dialyzed as described for MGC-RGD, and lyophilized to obtain MGC
functionalized with the IKVAV-containing peptide (MGC-IKVAV).
The degrees of methacrylation and peptide functionalization were determined by proton
nuclear magnetic resonance (1H NMR) spectroscopy, with targets of 5% for
methacrylation and 2.5% for peptide functionalization. The peptide-modified prepolymers were blended with unmodified MGC in a 40:60 ratio (MGC-peptide to MGC)
to obtain a final peptide concentration of 1.18 mM for both the MGC-RGD and MGCIKVAV groups.

2.1.2
2.1.2.1

Hydrogel Physical Characterization
Hydrogel Preparation

Lyophilized MGC, MGC-RGD or MGC-IKVAV was transferred into a sterile tissue
culture plate and sterilized by exposure to low-intensity UV light for 30 min. The MGC,
MGC-RGD and MGC-IKVAV hydrogels were prepared by dissolving the pre-polymer in
sterile deionized water (for sol content assessment) or PBS (for mechanical
characterization) at 2.5%, 2.71% and 3.13% (w/v) respectively, to account for differences
due to the weight of the peptide groups. The pre-polymer was dissolved overnight at
37°C under agitation at 700 RPM.
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Stock solutions of ammonium persulfate (APS; BioShop Canada Inc., Burlington, ON)
and N,N,N’,N’-tetramethylethylenediamine (TEMED; BioShop Canada Inc., Burlington,
ON) were prepared in water (for sol content assessment) or PBS (for mechanical
characterization), both at a concentration of 200 mM. For each hydrogel group, a 1 mL
solution comprising of 95% dissolved pre-polymer, 2.5% APS and 2.5% TEMED was
prepared and mixed well through gentle stirring. The mixture was transferred into a 1 mL
syringe and immediately placed in an incubator at 37°C for 15 min to facilitate crosslinking.

2.1.2.2

Sol Content Measurement

The cross-linking efficiency of the unseeded MGC, MGC-RGD and MGC-IKVAV
hydrogels was determined by measuring the sol content of the hydrogels.140 Immediately
following cross-linking, the hydrogels were cut into 500 μL samples (n=2) and snapfrozen in liquid nitrogen. The hydrogels were lyophilized for 12 h and the total dry mass
(mdry,total) was recorded. Each hydrogel was incubated at 37°C in 2 mL of deionized water
for 18 hours, with water exchanges at 6-h intervals. Following extraction of the residual
unreacted pre-polymer, the hydrogels were snap-frozen in liquid nitrogen and lyophilized
for 12 h. The lyophilized hydrogels were re-weighed to obtain the dry mass of polymer
incorporated into the network (mdry,network). The sol content was calculated using the
following equation:
Sol Content % =

2.1.2.3

,-./,12134 5 ,-./,67182.9
(,-./,12134 )

× 100%

Equilibrium Compressive Modulus Measurement

Mechanical testing was conducted by Stuart Young (PhD candidate, Amsden lab;
Queen’s University) to measure the equilibrium compressive modulus of the MGC,
MGC-RGD and MGC-IKVAV hydrogels.201 Following cross-linking, 50 μL hydrogels
(n=6) were swollen to equilibrium in PBS (pH 7.4). The dimensions of the swollen
hydrogels were measured using digital calipers immediately before testing. Unconfined
stress-relaxation measurements were conducted using a MACH-1™micromechanical
tester (Biomomentum Inc., Laval, QC) with a 1 kg load cell equipped with an upper steel
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plate and an advancing steel base. Each hydrogel was placed on the stage in a PBS bath.
Compression was applied axially at increments of 4% strain at a rate of 10%·s-1 to a total
strain of 32%, at which point the nominal stress-strain curve achieved plateau. The
resulting force decay was recorded at each step until an equilibrium stress was reached.
Nominal stress was calculated from the applied force divided by the initial cross sectional
area of the sample. The equilibrium compressive modulus was then obtained from the
slope of the linear region of the nominal equilibrium stress-stain curve.

2.2 Adipose-derived Stem/Stromal Cell (ASC) Isolation,
Culture, and Characterization
2.2.1

Adipose Tissue Collection

Abdominal and breast adipose tissue samples were collected from female patients
undergoing elective plastic and reconstructive procedures at the London Health Sciences
Centre in London, Ontario. Informed consent was obtained prior to surgery, and the study
was reviewed and approved by the Human Research Ethics Board at Western University
(REB #105426). Freshly-harvested adipose tissue samples were placed in 100 mL of
sterile, cation-free phosphate buffered saline (PBS; Lonza, Mississauga, ON)
supplemented with 20 mg/mL bovine serum albumin (BSA). The samples were
transported to the lab on ice and adipose-derived stem/stromal cell (ASC) isolation was
performed within 2 h of tissue collection. Patient age, weight, height and explant site
were recorded for all donors.

2.2.2

ASC Isolation

Human ASCs were isolated using established protocols as described in Flynn et al.202 The
fresh adipose tissue was finely minced using sterile scissors and any fibrous or cauterized
tissue was removed from the sample. The minced tissue was added to 25 mL of digest
solution consisting of 2 mg/mL collagenase type I (Worthington Biochemical Corp.,
Lakewood, NJ), 3 mM glucose, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) and 20 mg/mL BSA in Kreb’s Ringer Buffer (KRB) to a maximum
volume of 40 mL. The tissue was enzymatically digested for 45 min at 37°C under
constant agitation at 100 RPM. Undigested tissue fragments were removed by filtration
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through a 250 μm pore-size stainless steel filter and the filtrate was allowed to gravity
separate for 5 min. The upper layer of mature adipocytes was carefully aspirated without
disturbing the lower layer containing the stromal vascular fraction (SVF), including the
ASC population. To neutralize the collagenase, an equal volume of complete cell culture
medium comprised of Dulbecco’s Modified Eagle Medium:Ham’s F12 nutrient mixture
(DMEM:Ham’s F12), supplemented with 10% fetal bovine serum (FBS; Wisent Bio
Products, Montreal, QC) and 1% penicillin-streptomycin (pen-strep; Life Technologies
Inc., Burlington, ON) was added to the sample before centrifugation at 1200 × g for 5
min. The supernatant was discarded and the cell pellet was resuspended in 20 mL of
erythrocyte lysing buffer (0.154 M NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA in sterile
deionized water) for 10 min under agitation at 100 RPM before re-centrifugation. The
supernatant was aspirated and the cell pellet was resuspended in 20 mL of complete cell
culture medium. The cell suspension was filtered through a 100 μm pore-size nylon filter,
and re-centrifuged. The cell pellet was resuspended in complete medium and the cells
were plated onto T-75 tissue culture polystyrene (TCPS) flasks (Corning, New York,
USA) at 30,000 cells/cm2. After a 24 h incubation at 37°C (20% O2/5% CO2), the cells
were washed with 10 mL of sterile PBS to remove unattached cells and cellular debris,
and the complete medium was replaced.

2.2.3

ASC Culture and Cryopreservation

The complete medium was exchanged every 2 days until 80% confluence. Plastic
adherent cells were released through incubation at 37°C in 0.25% trypsin/0.1% EDTA
(Life Technologies Inc., Burlington, ON) for 5 min. The passage 1 (P1) cells were
collected, centrifuged and resuspended in cell freezing medium comprised of 80% FBS,
10% DMEM:Ham’s F12 medium and 10% dimethyl sulfoxide (DMSO; Fisher Scientific,
Ottawa, ON) at a concentration of 1 × 106 cells/mL. The ASCs were subjected to a
controlled freezing protocol using a freezing container at -80 °C (Nalgene, 5100-0001)
and stored in liquid nitrogen in a cryopreservation unit (Thermo Scientific CY509107)
until further use.
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2.2.4

ASC Expansion

Cryopreserved P1 ASCs were thawed and plated on T-75 flasks at a density of 1 × 106
cells per flask in complete medium, and cultured at 37°C (20% O2/5% CO2). The
complete medium was exchanged every 2 days. At 80% confluence, the ASCs were
trypsin-released and plated on new T-75 flasks in a 1 to 3 ratio. Passage 3 (P3) cells were
used for all cell characterization and encapsulation experiments. All studies included 2-3
technical replicates for all scaffold conditions seeded with ASCs from the same donor
(n=2-3), and the experiments were repeated to have 2-4 biological replicates using cells
from different donors (N=2-4).

2.2.5

ASC Immunophenotype Characterization

ASC immunophenotype was assessed by flow cytometry (n=3, N=3) using a Guava®
easyCyte 8HT benchtop flow cytometer (EMD Millipore Corp., USA) following
published protocols.203 Single marker staining was performed with monoclonal
flourophore-conjugated anti-human antibodies (eBioscience, San Diego, CA) as follows:
CD90 (Cat. # 11-0909-41), CD44 (Cat. # 25-0441-81), CD29 (Cat. # 12-0299-71), CD73
(Cat. # 11-0739-41), CD105 (Cat. # 12-1057-41), CD31 (Cat. # 12-0319-42), CD45 (Cat.
# 11-0459-41), CD146 (Cat. # 11-1469-41) and CD34 (Cat. # 17-0349-41). Controls of
unstained cells were also included in all analyses.
Passage 2 (P2) ASCs were trypsin-released, centrifuged and resuspended in complete
medium. A total viable cell count was performed on the ASCs using the Guava®
ViaCount Assay (Millipore Corp.). Cells were resuspended at a density of 2.4 × 105
cells/mL in PBS supplemented with 10% FBS. For each marker, 1 mL of cell suspension
was transferred into an eppendorf tube, and centrifuged at 1200 × g for 5 min at 4°C in a
pre-cooled micro-centrifuge. The supernatant was aspirated and the ASCs were
resuspended in 600 μL of ice-cold PBS supplemented with 3% BSA (PBS + 3% BSA).
All subsequent steps were performed under minimal lighting. 5 μL of the stock antibody
solution was added to the cell suspension. The samples were vortexed briefly and
incubated for 30 min at 4°C. The cells were washed 3 times by centrifuging at 400 × g for
5 min at 4°C, aspirating the supernatant, and resuspending the ASCs in 600 μL of ice36

cold PBS + 3% BSA. After the final wash, the cells were fixed in 0.5% paraformaldehyde
(Fisher Scientific, Ottawa, ON) for 15 min at 4°C. The cells were washed again with icecold PBS + 3% BSA for a total 3 rinses, and then stored in a dark environment at 4°C
until flow cytometry was performed.

2.3 ASC Encapsulation within the Hydrogels
The MGC, MGC-RGD or MGC-IKVAV pre-polymer solution and APS/TEMED
reagents were prepared in sterile PBS, as described in Section 2.1.2.1. P2 ASCs were
trypsin-released and resuspended at 5 × 107 cells/mL in complete medium. For each
hydrogel group, a 1 mL solution comprising of 75% pre-polymer, 20% cell suspension,
2.5% APS and 2.5% TEMED was prepared and mixed well through gentle stirring. The
mixture was transferred into a 1 mL syringe and immediately placed in an incubator at
37°C for 15 min to facilitate cross-linking. Following gelation, the cross-linked hydrogel
was extruded from the syringe and cut into 50 μL cylinders, each containing ~500,000
encapsulated ASCs. Each hydrogel was transferred into an individual 12-well insert
(Greiner Bio-one, North Carolina, USA) and cultured in complete medium.
To simulate the hypoxic microenvironment prevalent in the extremities of CLI
patients,115,204,205 the ASC-encapsulated hydrogels were cultured at 37°C under simulated
hypoxic conditions (2% O2/5% CO2/93% N2) in a Whitley H35 Hypoxystation
(HypOxygen, Maryland, USA). The complete medium was exchanged every 2 days for
the duration of the studies.

2.4 In Vitro Characterization of ASC following
Encapsulation
2.4.1

ASC Viability

ASC viability following encapsulation and culture in the various hydrogel groups (MGC,
MGC-RGD, MGC-IKVAV) was assessed at 24 h, 7 d and 14 d using the LIVE/DEAD®
Viability/Cytotoxicity Kit for mammalian cells (Life Technologies Inc., Burlington, ON)
involving staining with calcein AM and ethidium homodimer-1 (EthD-1) (n=3, N=3). At
each time point, the hydrogels were rinsed with PBS and stained with 2 μM calcein AM
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and 4 μM EthD-1 at 37°C for 1 h. Following incubation, triplicate samples of each
hydrogel group were imaged using a 5× objective lens on a Zeiss LSM 800 confocal
microscope (ZEISS, Canada). The mosaic stitch technique was used to capture the entire
cross-sectional area of the hydrogel.141 A total of 4-5 layers were scanned and imaged for
each hydrogel along its depth (z-axis), with each layer separated by 50 μm. The images
were then processed to quantify the number of calcein+ live cells and EthD-1+ dead cells
using Image J analysis software. The ASC viability was calculated as a percentage of the
live to total cells, and the average number of live and dead cells per plane was also
determined for each sample.

2.4.2
The

ASC Metabolic Activity
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide

(MTT;

Life

Technologies Inc., Burlington, ON) assay was used to measure the metabolic activity of
ASCs encapsulated in the MGC, MGC-RGD or MGC-IKVAV hydrogels at 24 h, 7 d and
14 d (n=3, N=3).206 Unseeded hydrogels were also analyzed as a control. A working MTT
solution (0.5 mg/mL) was prepared in DMEM:Ham’s F12 medium. The hydrogel
samples were submerged in 2 mL of MTT solution, and incubated at 37°C for 4 hours.
Following incubation, each hydrogel was washed twice with sterile PBS and weighed.
The hydrogels were transferred into 1.5 mL eppendorf tubes with 800 μL of DMSO and
manually crushed using a plastic eppendorf pestle. The samples were then incubated for 1
h at 37°C under gentle agitation at 100 RPM to extract the water-insoluble formazan
product. The supernatant was collected following centrifugation at 15,000 × g for 15 min,
and the samples were diluted 1:1 in DMSO. The samples were vortexed briefly and 200
μL of sample was pipetted into a 96-well plate in triplicate. Sample absorbance was
measured at 540 nm and corrected for background absorbance at 690 nm using a
CLARIOstar® High Performance Monochromator Multimode Microplate Reader (BMG
Labtech, Guelph, ON). To account for minor differences in gel size, the data was
normalized based on individual gel weight (mg). The average normalized absorbance of
the unseeded controls for each of the hydrogel groups was subtracted to account for any
non-specific background associated with the hydrogels.
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2.4.3

ASC Angiogenic Gene Expression

The human angiogenesis RT2 Profiler™PCR array (Qiagen, Toronto, ON) was used to
assess the mRNA expression of 84 genes associated with angiogenesis in the ASCs
encapsulated within the MGC, MGC-RGD, and MGC-IKVAV hydrogels (N=4). ASCs
cultured in 2-D on uncoated TCPS were included as a calibrator to normalize the levels
between donors. The RNeasy® kit (Qiagen, Toronto, ON) was used to extract the total
RNA from the hydrogels or TCPS controls cultured under simulated hypoxic conditions
(2% O2) for 7 d.207 For each hydrogel group, triplicate samples of two hydrogels were
rinsed with PBS and minced with scissors in 1 mL of TRIzol reagent (n=6 total per
hydrogel group). The samples were then disrupted using an ultrasonic homogenizer with
3 sets of 10-second bursts with intervals of cooling on ice, followed by 5 min incubation
at room temperature. To prepare the TCPS controls, 500,000 P3 ASCs were seeded in
individual wells of a 6-well plate and cultured under simulated hypoxic conditions (2%
O2). At 7 d, the cells were rinsed with PBS and incubated in 1 mL of TRIzol reagent for 5
min. For both the hydrogel samples and TCPS controls, 200 μL of chloroform was added
and the samples were incubated at room temperature for 10 min before centrifugation at
10,000 × g for 10 min. The upper aqueous phase was transferred into new 1.5 mL
eppendorf tubes, and 250 μL of 70% ethanol was added to each sample. The samples
were transferred to RNeasy mini spin columns and processed according to the
manufacturer’s instructions. The triplicate samples were pooled (n=6 gels total) and postextraction clean-up was performed by adding 0.1× the volume of 3 M sodium acetate,
2.5× the volume of 100% ethanol, and 0.01× the volume of 5 mg/mL glycerol to the
aqueous RNA sample. After overnight incubation at -30°C, the RNA was washed with 30
μL of 80% ethanol 3 times with centrifugation at 12,000 × g for 30 min between each
wash. The RNA was resuspended in 30 μL of nuclease-free water, and sample
concentration and purity were determined using a NanoDrop 1000 spectrophotometer
(Thermo Scientific).
The RT2 First Strand kit (Qiagen, Toronto, ON) was used to prepare cDNA from the
extracted RNA. Each sample was first treated with a DNA elimination step by incubating
400 ng of RNA, 2 μL genomic-DNA elimination buffer and nuclease-free water for 5
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min at 42°C. Subsequently, 10 μL of the sample was mixed with 10 μL of reversetranscription mix containing 5× reverse transcription buffer, primer mix, RT enzyme mix
and RNase-free water. The samples were incubated at 42°C for 15 min and then at 95°C
for 5 min to stop the reaction.
Following manufacturer’s instructions for the PCR reactions, 91 μL of nuclease-free
water was added to each 20 uL cDNA sample and mixed well through pipetting. The
PCR component mix was prepared for each sample by mixing 102 μL of the diluted
cDNA sample with 650 μL of 2× RT2 SYBR Green Mastermix and 548 μL of RNase-free
water, for a total volume of 1300 μL. For each sample, 10 μL of the prepared PCR
component mix was dispensed into each well of the 384-well RT2 Profiler PCR array
plate. The plate was tightly sealed with optical adhesive film and centrifuged for 1 min at
1000 × g to remove any bubbles. The plate was run on a CFX384 Touch™Real-Time
PCR detection system (Bio-Rad, Mississauga, ON). The cycle threshold (Ct) values were
obtained and processed using the online software provided by Qiagen’s data analysis
center. The stably expressed housekeeping gene, ribosomal protein lateral stalk subunit
P0 (RPLP0), was used to normalize the data. Fold change in the mRNA expression of the
84 analyzed genes was used to compare the MGC, MGC-RGD and MGC-IKVAV groups
normalized to the TCPS control group. Genes displaying >2-fold upregulation or
downregulation in mRNA expression relative to the TCPS controls across all donors were
selected and statistically analyzed.

2.5 In Vivo Characterization of ASC Retention following
Encapsulation and Angiogenic Response to the
Hydrogels
2.5.1

Subcutaneous Implantation of Hydrogels in NOD/SCID Mice

A subcutaneous implantation model was used to assess cell retention and the angiogenic
potential of human ASCs encapsulated within the MGC, MGC-RGD or MGC-IKVAV
hydrogels. The animal studies were reviewed and approved by the Human Research
Ethics Board at Western University (REB #2016-015). Adult NOD/SCID mice (8-10
weeks old) used for this study were derived from Jackson laboratories: NOD.CB17-
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Prkdcscid/J; stock number: 001303. The NOD/SCID mice provide a favorable
microenvironment to support human cell engraftment and function due to reduced innate
immunity (NOD mutation), and complete T- and B-cell deficiency (SCID mutation).208
Each mouse was implanted with one seeded hydrogel and its corresponding unseeded
control. The 50 µL hydrogel samples were subcutaneously implanted on the dorsa of
each mouse, below each scapula, with surgical assistance from Stephen Sherman (PhD
candidate, Hess Lab) at the Robarts Research Institute. Two mice were used for each
hydrogel group and the study was repeated with ASCs from 3 different donors (n=2,
N=3).
Prior to surgery, the mice were injected with 42 mg/kg of ketamine hydrochloride and 1
mg/kg of xylazine, and the animals were maintained on 2% isoflurane (Baxter Corp.,
Mississauga, ON) during the surgical procedure. For each experimental group, one 50 μL
hydrogel containing ~500,000 encapsulated human ASCs was implanted in a
subcutaneous pocket created in the right dorsal flank, and a second 50 μL unseeded
hydrogel was implanted subcutaneously in the left dorsal flank. Mice were given 2 mg/kg
of metacam after the surgery.
At 24 h prior to euthanasia, the mice were intraperitoneally injected with 200 μg 5ethynyl-2'-deoxyuridine (EdU; Thermo Fisher, Waltham, MA) to label dividing cells.
After 14 days, the mice were anesthetized with isoflurane and euthanized by cervical
dislocation, and the scaffolds were excised within their surrounding tissues. The samples
were embedded in OCT medium (Tissue Tek, Sakura Finetek, Torrance, CA) and
cryosectioned (10 μm) with assistance from Gillian Bell (Research Assistant, Hess Lab)
at Robarts Research Institute.

2.5.2

Detection of Human ASCs and Murine CD31+ Cells

The sections were analyzed by immunofluorescence microscopy for human leukocyte
antigen (HLA)-ABC to label human ASCs,209 murine CD31 to visualize CD31+ cell
recruitment and EdU to assess cellular proliferation,208,209 along with DAPI
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counterstaining of nuclei. All incubation steps during staining were performed at room
temperature.
HLA-ABC staining: Sections were washed twice with PBS for 10 min and permeabilized
with 0.1% TritonX-100 for 20 min. The sections were washed again with PBS for 10 min
and incubated with a mouse-on-mouse (MOM) blocking agent (Vector Labs, Burlingame,
CA) for 1 h. The sections were incubated with MOM diluent for 5 min, and then with
mouse anti-human HLA-ABC antibody (1:100 dilution in MOM diluent; BD
Biosciences, Mississauga, ON) for 30 min. Next, the sections were washed twice with
PBS for 2 min, and incubated with fluorescein-labeled horse anti-mouse IgG (1:200
dilution in MOM diluent) for 30 min. Finally, the sections were washed twice with PBS
for 2 min, rinsed with deionized water, and mounted in VectaShield with DAPI (Vector
Labs, Burlingame, CA). Primary antibody negative controls (HLA-ABC−) were prepared
by substituting the mouse anti-human HLA-ABC antibody with MOM diluent.209
EdU and CD31 staining: Sections were washed twice with PBS for 10 min and
permeabilized with 0.1% Triton X-100 for 20 min. The sections were washed again with
PBS for 10 min, and incubated for 30 min with EdU labeling cocktail consisting of 860
μL reaction buffer, 100 μL buffer additive, 40 μL CuSO4 and 2.5 μL Alexa Fluor Azide
provided in the Click-iT™ imaging kit (Invitrogen, Burlington, ON). The sections were
washed twice with PBS for 2 min and blocked by incubation in rabbit serum (Vector
Labs, Burlingame, CA) for 1 h. The sections were then incubated with rat anti-mouse
CD31 antibody (1:100 dilution in rabbit serum) for 1 h. Next, the sections were washed
twice with PBS for 2 min and incubated with fluorescein-labeled rabbit anti-rat IgG
(1:200 dilution in rabbit serum) for 30 min. Finally, the sections were washed twice with
PBS, rinsed in deionized water, and mounted in VectaShield with DAPI (Vector Labs,
Burlingame, CA). EdU− controls were prepared by removing the CuSO4 reactioncatalyzing reagent from the EdU labeling cocktail. Primary antibody negative (CD31−)
controls were prepared by substituting the primary antibody with rabbit serum.208,209

42

2.5.3

Imagine and Quantification of HLA-ABC+, EdU+ and CD31+
Cells

Analysis of human ASC retention: Images of the immunostained sections were taken
with an Axioscope Z2 fluorescence microscope (ZEISS Germany), analyzing 8-10 nonoverlapping areas selected randomly within the scaffold per section, from a total of 3
sections per hydrogel implant using AxioVision software (n=2, N=3). Scaffold area was
calculated by converting each image to an 8-bit binary copy and using ImageJ software to
analyze the total scaffold area in mm2. The number of HLA-ABC+ DAPI+ cells were
counted for each image in a blinded fashion and expressed as the average number of
HLA-ABC+ DAPI+ cells/mm2 of hydrogel scaffold.
Analysis of murine CD31+ cell recruitment and proliferation: Images of the
immunostained sections were taken with an Axioscope Z2 fluorescence microscope,
analyzing 4-5 areas selected randomly at the scaffold-tissue boundary per section, from a
total of 3 sections per hydrogel implant using AxioVision software (n=2, N=2). The
number of CD31+ cells co-localized with visible DAPI-stained nuclei were counted for
each image in a blinded fashion and expressed as the mean number of CD31+ cells/mm2.
The number of CD31+ EdU+ DAPI-stained cells were also counted for each image in a
blinded fashion and reported as the number of proliferating CD31+ cells.

2.6 Statistical Analysis
All data are expressed as mean ± standard deviation, and the number of biological (N)
and technical (n) replicates are indicated for all experiments. Unless otherwise stated,
statistical analyses were performed using GraphPad Prism 6 by one-way or two-way
analysis of variance (ANOVA). Multiple comparisons were performed with Tukey’s
post-hoc comparison of means. Differences were considered statistically significant at
p<0.05.
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Chapter 3

3

RESULTS

3.1 Hydrogel Characterization
3.1.1

Sol Content Analysis

Sol content provides a measure of the amount of the methacrylated glycol chitosan
(MGC) pre-polymer that has not been incorporated into the hydrogel network during
cross-linking. A lower sol content value is desirable as it indicates higher cross-linking
efficiency. In comparing the 3 hydrogel groups, the sol content value for the MGCIKVAV group was 15.0 ± 0.9%, which was significantly higher than the values of 7.4 ±
0.1% for the non-peptide modified MGC group and 8.9 ± 0.9% for the MGC-RGD group
(Figure 3.1A), thus indicating that modification of the MGC with the IKVAV peptide
influenced the cross-linking process.

Figure 3.1. Sol content and equilibrium compressive moduli of MGC, MGC-RGD and MGCIKVAV hydrogels. (A) The cross-linking efficiency of each type of hydrogel was assessed by
measurement of the sol content following thermally-induced cross-linking and extraction in deionized
water (n=2). The MGC-IKVAV hydrogel group had a significantly higher sol content than the other
hydrogel groups, suggesting that modification with the IKVAV peptide may have interfered with
cross-linking process. (B) The equilibrium compressive modulus of the three hydrogel groups as
measured through micromechanical compression testing, confirming that all hydrogels had similar
mechanical properties (n=6). Data represents mean ± SD (*p<0.05).
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3.1.2

Equilibrium Compressive Modulus Analysis

The cross-linking efficiency can influence the mechanical properties of the resultant
hydrogels. Since the response of encapsulated cells can be impacted by both biochemical
and biomechanical effects,210–212 the equilibrium compressive moduli of the MGC, MGCRGD and MGC-IKVAV hydrogels were quantified to assess whether there were any
differences in gel stiffness between the groups. Despite the variation in the sol content for
the MGC-IKVAV group, there were no statistically significant differences in the
equilibrium compressive moduli of the hydrogels, with calculated values of 11.9 ± 1.3
kPa for the MGC group, 10.6 ± 2.1 kPa for the MGC-RGD group, and 12.0 ± 0.9 kPa for
the MGC-IKVAV group (Figure 3.1B). Based on this analysis, it was decided that no
further optimization of the hydrogel formulation was required, as the equivalent
compressive moduli controlled for the possible confounding effects of the hydrogel
biomechanical properties in assessing the impact of the peptide groups on cell function.

3.2 Adipose-derived Stromal/Stem Cell (ASC)
Immunophenotype Analysis
The immunophenotype of passage 3 (P3) human adipose-derived stem/stromal cells
(ASCs) expanded on tissue culture polystyrene (TCPS) was assessed by flow cytometry
(Figure 3.2). Consistent with the expected expression of stromal cell markers, ASCs
dependably expressed CD90 (99.8 ± 0.1%), CD44 (99.6 ± 0.2%), CD29 (95.8 ± 2.6%),
CD73 (84.7 ± 8.1) and CD105 (97.2 ± 2.2%). Further, ASCs showed minimal expression
of the endothelial cell marker CD31 (0.3 ± 0.2%) and the hematopoietic pan-leukocyte
marker CD45 (1.3 ± 1.2%). The pericyte marker CD146 (4.6 ± 3.2%) and the progenitor
cell marker CD34 (0.6 ± 0.1%) demonstrated low expression, consistent with previous
studies reporting a steady decline in the expression of these markers during culture and
successive passaging.100,213,214 Overall, the immunophenotype of the ASCs used in this
study was consistent with the guidelines established by the International Society of
Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and
Science (IFATS) for human ASCs.112
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Figure 3.2. Immunophenotype of human ASCs at passage 3. (A) Representative flow cytometry
histograms showing expression of analyzed cell surface markers. Unstained controls are shown in
light grey. (B) Frequency of cells expressing each of the analyzed markers. The ASC
immunophenotype was consistent with guidelines set forth by the International Federation for Adipose
Therapeutics (IFATS) and the International Society for Cellular Therapy (ISCT), with high expression
(>80%) of CD90, CD44, CD29, CD73 and CD105, and low expression (<2%) of CD31 (endothelial)
and CD45 (hematopoietic). Data represents mean ± SD (p<0.05; n=3, N=3).
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3.3 ASC Encapsulation within Hydrogels
Human ASCs at P3 were encapsulated within the MGC, MGC-RGD and MGC-IKVAV
hydrogels at a concentration of 10 × 106 ASCs/mL through thermally-induced free radical
polymerization

with

ammonium

persulfate

(APS)

and

N,N,N’,N’-

tetramethylethylenediamine (TEMED) as the initiator system. Immediately after gelation,
50 μL hydrogel cylinders containing ~500,000 encapsulated ASCs were generated
(Figure 3.3) and used for all subsequent in vitro and in vivo studies.

Figure 3.3. Representative images of an MGC hydrogel containing encapsulated ASCs. (A)
Human ASCs were encapsulated within a 50 μL MGC hydrogel at a concentration of 10 × 106
ASCs/mL. Light photomicrographs taken at 24 h following encapsulation showing the ASCs
(examples indicated with white arrows) distributed within the MGC hydrogel at (B) 4× and (C) 20×
magnification.
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3.4 In Vitro Analysis of ASCs following Encapsulation
3.4.1

ASC Viability

The LIVE/DEAD® assay with confocal imaging analysis was used to assess ASC
viability following encapsulation within the MGC, MGC-RGD or MGC-IKVAV
hydrogels over 14 days in culture under a simulated hypoxic environment (2% O2)
(Figure 3.4). Quantitative analysis revealed that ASC viability in the MGC (86.6 ± 4.5%)
and MGC-RGD (87.4 ± 2.7%) hydrogels was significantly higher than the MGC-IKVAV
(73.3 ± 12.3%) group at 24 h (Figure 3.4B). The high viability in the MGC and MGCRGD groups validated that the radically-induced thermal cross-linking approach using
APS and TEMED did not adversely impact cell viability.
Analysis of ASC viability over time revealed that cell viability was also significantly
reduced in the MGC-IKVAV hydrogel group relative to the MGC and MGC-RGD
groups at both 7 and 14 d. ASC viability significantly declined from 24 h to 14 d in both
the MGC and MGC-IKVAV hydrogel groups, from 86.6 ± 4.5% to 75.0 ± 6.6% for the
MGC group and 73.3 ± 12.3% to 54.4 ± 12.2% for the MGC-IKVAV group (Figure
3.4B). In contrast, there was no significant difference observed in ASC viability over
time in the MGC-RGD group, with >80% viability observed over the course of the study.
To complement the viability analysis, the average number of live and dead ASCs within
each hydrogel cross-section was plotted for the MGC, MGC-RGD and MGC-IKVAV
hydrogel groups at each time point (Figure 3.4C). Notably, there was no significant
difference in the total number of cells per plane (live + dead) for all hydrogel groups.
However, at both 7 d and 14 d, there was significantly lower number of live cells in the
MGC-IKVAV group relative to both the MGC and MGC-RGD groups, with a significant
decline in the number of live cells observed over time from 24 h to 14 d.
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Figure 3.4. Viability analysis of ASCs encapsulated within MGC, MGC-RGD and MGC-IKVAV
hydrogels cultured under simulated hypoxic conditions (2% O2). (A) Representative confocal
microscopy photomicrographs of LIVE/DEAD®-stained ASCs encapsulated within an MGC hydrogel
at 24 h. Live cells (upper row; green) and dead cells (bottom row; red) were imaged across 4 planes
within the hydrogel using a mosaic stitch technique to visualize the entire cross-section of the scaffold
at varying depths. (B) The number of live and dead cells were quantified to assess the percent viability
of the ASCs in each of the hydrogel groups at 24 h, 7 d and 14 d. The MGC-IKVAV hydrogel had
significantly lower ASC viability than the other hydrogel groups across each time-point. ASC viability
declined in the MGC and MGC-IKVAV groups from 24 h to 14 d, but no significant differences in
viability were observed over time for the MGC-RGD group. (C) The average number of live (lower
bar) and dead (upper bar) ASCs within each hydrogel group at 24 h, 7 d and 14 d based on the
LIVE/DEAD® assay. The MGC-IKVAV hydrogel demonstrated a significantly reduced number of
live ASCs at 7 d and 14 d compared to the other hydrogel groups, as well as a significant decline in
live ASCs between 24 h and 14 d. Data represents mean ± SD (*p<0.05; n=3, N=3).

3.4.2

ASC Morphology

The confocal imaging analysis in the LIVE/DEAD® assay also enabled the assessment of
qualitative changes in ASC morphology following encapsulation and culture (Figure 3.5).
At 24 h, the ASCs in all three hydrogel groups had a rounded morphology. Following
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culture, ASCs with a distinct elongated fibroblastic morphology were observed within the
two most superficial planes (0-50 µm) of the MGC-RGD hydrogel group, with a
qualitative increase noted in the frequency of spreading from 7 to 14 d (Figure 3.5E&F).
In contrast, ASCs encapsulated in the MGC and MGC-IKVAV hydrogels maintained a
rounded shape over the course of the study.

Figure 3.5. Representative photomicrographs of LIVE/DEAD®-stained ASCs encapsulated
within MGC, MGC-RGD or MGC-IKVAV hydrogels cultured under simulated hypoxic
conditions (2% O2). Photomicrographs showing live cells (green) and dead cells (red) within each
hydrogel group at 24 h, 7 d, and 14 d. White arrows indicate ASCs with an elongated morphology in
the superficial plane of the MGC-RGD hydrogel group at 7 and 14 d.
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3.4.3

ASC Metabolic Activity

In order to more fully examine ASC viability and function following encapsulation
within the various hydrogels, the MTT assay was performed to assess the metabolic
activity of ASCs encapsulated within the MGC, MGC-RGD or MGC-IKVAV hydrogels
over 14 days in culture under simulated hypoxic conditions (2% O2) (Figure 3.6). The
metabolic activity of the encapsulated ASCs significantly decreased between 24 h and 7 d
for all hydrogel groups, and was then maintained at similar levels at 14 d. In comparing
the groups, the ASCs encapsulated within the MGC-IKVAV hydrogels had significantly
lower metabolic activity than the MGC and MGC-RGD groups at 24 h and 7 d. At 14 d,
the metabolic activity was significantly higher in the MGC-RGD hydrogels as compared
to the other groups.

Figure 3.6. Metabolic activity of ASCs encapsulated within MGC, MGC-RGD and MGCIKVAV hydrogels cultured under simulated hypoxic conditions (2% O2). The MTT assay was
performed at 24 h, 7 d and 14 d following ASC encapsulation. The absorption intensity was
normalized to the gel weight (mg) to account for minor differences in the size of the individual
hydrogels. All hydrogel groups demonstrated a significant decrease in ASC metabolic activity from 24
h to 7 d, and then levels were sustained at 14 d. The MGC-IKVAV hydrogel showed significantly
lower ASC metabolic activity at 24 h and 7 d as compared to the MGC and MGC-RGD hydrogel
groups. The MGC-RGD hydrogel group demonstrated a significantly higher ASC metabolic activity at
14 d as compared to both the MGC and MGC-IKVAV groups. Data represents mean ± SD (*p<0.05;
n=3, N=3).
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3.4.4

ASC Angiogenic Gene Expression

The human angiogenesis RT2 Profiler™PCR array was used as a high throughput
screening approach to assess the potential effects of 3-D hydrogel encapsulation and
MGC peptide modification on the mRNA expression of 84 genes associated with
angiogenesis in ASCs encapsulated within the MGC, MGC-RGD or MGC-IKVAV
hydrogels in comparison to 2-D TCPS controls after 7 days of culture under simulated
hypoxic conditions (2% O2). Genes that demonstrated >2-fold change relative to the
TCPS controls across all cell donors (N=4) were selected for further statistical analysis.

3.4.4.1

Upregulated Angiogenesis-associated Genes

There was a >2-fold upregulation in gene expression of several secreted angiogenic
factors including hepatocyte growth factor (HGF), vascular endothelial growth factor A
(VEGFA), angiopoietin-like 4 (ANGPTL4) and angiopoietin-2 (ANGPT2) in the
encapsulated ASCs as compared to the TCPS controls (Figure 3.7). In general, the most
notable differences were associated with culturing the ASCs in the 3-D hydrogels versus
the 2-D culture conditions, rather than due to the effects of modifying the MGC with the
peptide ligands. For a number of the genes, there was significant variability in the
magnitude of the expression between donors, so the data was plotted separately to show
the response of the individual donors, as well as the averaged values used for statistical
analysis.
When comparing the hydrogel groups, a trend for enhanced HGF gene expression was
noted in the MGC group relative to both peptide-modified MGC groups across all four
donors. Moreover, the pooled values indicated that there was a significant difference in
HGF expression between the MGC and MGC-IKVAV groups (Figure 3.7A). For
VEGFA, ANGPTL4 and ANGPT2, the mRNA expression levels were significantly
upregulated in the MGC, MGC-RGD, and MGC-IKVAV groups relative to the TCPS
controls, but there were no notable differences between the various hydrogel groups in
comparing the response of all cell donors (Figure 3.7B-D).
A >2-fold upregulation in gene expression was also noted in comparing the hydrogels to
the TCPS controls for the extracellular matrix (ECM) protein collagen XVIII α1
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(COL18A1), the matrix-remodeling factor matrix metalloproteinase 14 (MMP14), and the
cell adhesion glycoprotein integrin β3 (ITGB3) (Figure 3.8). For COL18A1, there was a
trend for enhanced mRNA expression in the MGC group relative to the MGC-RGD and
MGC-IKVAV groups for 3 out of 4 of the cell donors, but the only significant difference
noted in the pooled values was between the MGC group and the 2-D TCPS control
(Figure 3.8A). Similarly, for MMP14, significantly higher expression levels were noted
in the MGC hydrogel group as compared to the TCPS control, but there were no notable
differences between the hydrogel groups (Figure 3.8B). Finally, while there was a trend
for enhanced ITGB3 expression in all three hydrogel groups relative to the 2-D controls,
the difference in the pooled data was not statistically significant and the expression levels
were relatively consistent across all 3 hydrogel groups (Figure 3.8C).

3.4.4.2

Downregulated Angiogenesis-associated Genes

A >2-fold downregulation was observed in the gene expression levels of the secreted
factors thrombospondin-1 (THBS1), angiopoetin-1 (ANGPT1), connective tissue growth
factor (CTGF) and fibroblast growth factor 1 (FGF1) in the ASCs encapsulated in the
hydrogels as compared to the TCPS controls for all cell donors (Figure 3.9). For 3 out of
4 of the cell donors studied, there was a trend for reduced mRNA expression of the antiangiogenic factor THBS1 in the MGC-IKVAV group relative to both the MGC and
MGC-RGD groups. Moreover, analysis of the pooled data indicated that there was a
significant difference in the THBS1 expression levels between the MGC-IKVAV group
and the TCPS controls (Figure 3.9A). Similarly, for 2 of the 4 cells donors, the
expression of the angiogenic factor ANGPT1 was downregulated in the MGC-IKVAV
group relative to all other groups, with a significant difference observed in the pooled
data relative to the TCPS controls (Figure 3.9B). There were no obvious trends in
comparing the expression levels of CTGF and FGF1 between the hydrogel groups across
all 4 cell donors (Figure 3.9C&D). However, in analyzing the pooled data, there was a
significant reduction in CTGF gene expression in the MGC-IKVAV group relative to the
TCPS controls, as well as significantly lower levels of FGF1 mRNA expression in all
three hydrogel groups relative to the 2-D controls.
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Figure 3.7. Gene expression of upregulated secreted angiogenic factors in ASCs encapsulated within MGC, MGC-RGD or MGC-IKVAV
hydrogels and cultured under simulated hypoxic conditions (2% O2). Results are expressed as fold change in the mRNA expression at 7 d relative to
TCPS controls. Gene expression of (A) HGF was significantly enhanced in the MGC hydrogel group compared to the TCPS controls, and also compared
to the MGC-IKVAV hydrogel. Transcript levels of (B) VEGF, (C) ANGPTL4 and (D) ANGPT2 were significantly upregulated for all hydrogel groups
relative to the TCPS controls, suggesting enhanced transcription of these pro-angiogenic factors in the ASCs encapsulated in the hydrogels. Data shows
transcript levels from the individual donors (left) and the pooled data from all 4 donors expressed as mean ± SD (right) (*p<0.05; n=6, N=4).
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Figure 3.8. Gene expression of upregulated ECM-associated factors in ASCs encapsulated within MGC, MGC-RGD or MGC-IKVAV hydrogels
and cultured under simulated hypoxic conditions (2% O2). Results are expressed as fold change in the mRNA expression at 7 d relative to the TCPS
controls. Gene expression of (A) the ECM protein COL18A1 and (B) the matrix remodeling factor MMP14 were significantly upregulated in the MGC
hydrogel group relative to TCPS controls, suggesting enhanced transcription of regulatory and remodeling proteins involved in angiogenic processes in
the encapsulated ASCs. (C) A trend for enhanced transcript levels of ITGB3 was noted for all hydrogel groups relative to the TCPS controls for all 4 cell
donors, but the difference was not significant. Data shows transcript levels from the individual donors (left) and the pooled data from all 4 donors
expressed as mean ± SD (right) (*p<0.05; n=6, N=4).
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Figure 3.9. Gene expression of downregulated secreted factors in ASCs encapsulated within MGC, MGC-RGD or MGC-IKVAV hydrogels and
cultured under simulated hypoxic conditions (2% O2). Results are expressed as fold change in the mRNA expression at 7 d relative to the TCPS
controls. The mRNA expression of (A) THBS1, (B) ANGPT1 and (C) CTGF was significantly decreased in the MGC-IKVAV hydrogel group as
compared to the TCPS controls. Transcript levels of (D) FGF1 were significantly downregulated in all hydrogel groups relative to the TCPS controls.
Data shows transcript levels from the individual donors (left) and the pooled data from all 4 donors expressed as mean ± SD (right) (*p<0.05; n=6, N=4).
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3.5 In Vivo Analysis of ASCs following Encapsulation
3.5.1

ASC Retention within the Implanted Hydrogels

Human ASCs were encapsulated within the MGC, MGC-RGD or MGC-IKVAV
hydrogels and subcutaneously implanted into NOD/SCID mice to assess whether peptide
modification of the MGC influenced ASC retention within the hydrogels in vivo. At 14 d
post-transplantation, the animals were euthanized to collect the hydrogels, which were
easily visualized within the subcutaneous space (Figure 3.10A). Immunostaining for
HLA-ABC was performed to detect human cells (Figure 3.10B), and quantitative analysis
revealed that there were significantly more HLA-ABC+ cells per unit area in the gel phase
of the MGC-RGD hydrogel group at 144 ± 31 cells/mm2 as compared to the MGCIKVAV hydrogel group at 67 ± 16 cells/mm2 (Figure 3.10C). While there was a trend for
a higher density of HLA-ABC+ cells in the MGC-RGD group as compared to the nonpeptide modified MGC hydrogel group (103 ± 27 cells/mm2), the difference was not
statistically significant.
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Figure 3.10. Analysis of human ASC retention within subcutaneously implanted MGC, MGCRGD or MGC-IKVAV hydrogels. (A) Representative photograph of an unseeded (left) and ASCseeded (right) MGC hydrogel subcutaneously implanted into NOD/SCID mice and excised at 14 d.
(B) Representative immunohistochemical photomicrographs of HLA-ABC+ (bright green) and DAPI
(blue) stained human ASCs within the hydrogels (lighter green due to autofluorescence). (C) Mean
number of HLA-ABC+ DAPI+ human ASCs/mm2 visualized within each of the hydrogel groups. The
MGC-RGD hydrogel showed significantly higher ASC retention within the scaffold at 14 d as
compared to the MGC-IKVAV hydrogel group. Data represents mean ± SD analyzing 8-10 nonoverlapping frames within the scaffold per section, from a total of 3 sections per hydrogel sample
(*p<0.05; n=2, N=3).
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3.5.2

CD31+ Cell Recruitment and Proliferation in the Peri-implant
Region

Murine endothelial cell (EC) and myeloid cell recruitment and proliferation were
assessed within the host tissues in the peri-implant region (Figure 3.11) immediately
adjacent to the MGC, MGC-RGD and MGC-IKVAV implants at 14 d through
immunostaining for CD31, combined with EdU incorporation to detect proliferating
CD31+ cells (Figure 3.12A). CD31, named platelet-derived endothelial cell adhesion
molecule, is a well-accepted endothelial cell marker, but is also expressed on early
myeloid cells and macrophages.215 Unseeded control hydrogels were also included in the
analysis to more fully characterize the influence of the encapsulated ASCs versus the
hydrogel alone on CD31+ cell recruitment in vivo.

Figure 3.11. Representative immunohistochemical photomicrograph showing the peri-implant
region in the subcutaneous hydrogel implants. The peri-implant region was identified by DAPI
nuclear staining as the dense cell layer immediately adjacent to the implanted hydrogel.
Photomicrograph shows CD31+ cells (green) and proliferating cells (EdU+, pink nuclei; examples
indicated with white arrows) within the peri-implant region at 14 d post-transplantation.
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A significantly higher number of murine CD31+ cells were detected in the surrounding
tissues of the ASC-seeded MGC (168 ± 5 cells/mm2) and MGC-RGD (161 ± 12
cells/mm2) hydrogels as compared to their corresponding unseeded controls (89 ± 14
cells/mm2 and 94 ± 7 cells/mm2, respectively) (Figure 3.12B). In contrast, there was no
difference noted in CD31+ cell recruitment between the seeded (113 ± 31 cells/mm2) and
unseeded (97 ± 4 cells/mm2) hydrogels for the MGC-IKVAV group. Analysis of EdU
incorporation indicated that there were proliferating CD31+ cells in the peri-implant
regions. However, there was significant variability in the number of proliferating cells,
with no statistically significant differences observed between any of the groups (Figure
3.12C).
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Figure 3.12. Analysis of CD31+ cell recruitment and proliferation in the peri-implant region of
subcutaneously-implanted MGC, MGC-RGD or MGC-IKVAV hydrogels. (A) Representative
photomicrographs of CD31+ (green) and proliferating cells (EdU+, pink nuclei) within the host tissues
surrounding the ASC-seeded or unseeded hydrogels at 14 d post-transplantation. (B) Mean number of
CD31+ cells recruited to the peri-implant region for each type of hydrogel with or without ASCs.
ASC-seeded MGC and MGC-RGD hydrogels had a significantly higher number of CD31+ cells within
the peri-implant region as compared to their corresponding unseeded controls, suggesting that ASCs
may provide paracrine signals that promote CD31+ cell recruitment. (C) Frequency of CD31+ EdU+
cells within the peri-implant region of the ASC-seeded and unseeded hydrogel groups. No significant
differences in CD31+ proliferation were observed between any of the groups. Data represents mean ±
SD analyzed from 4-5 non-overlapping frames at the scaffold-tissue boundary per section, from a total
of 3 sections per hydrogel sample (*p<0.05; n=2, N=2).
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Chapter 4

4

DISCUSSION

There is growing interest in the design and application of biomaterials as cell delivery
vehicles to improve the efficacy of cell-based treatments for peripheral artery disease
(PAD). A range of synthetic, semi-synthetic and naturally-derived biomaterials have been
explored to enhance the localization, retention and function of pro-regenerative cell
populations.85 Notably, hydrogels have shown promise as cell delivery scaffolds for
therapeutic angiogenesis due to their capacity to cross-link in situ under mild conditions
to enable minimally-invasive cell delivery via intramuscular injection.216 Hydrogels also
have high water content similar to that of the native extracellular matrix (ECM), which
allows for efficient nutrient exchange and supports in vivo integration with minimal
mechanical irritation to the surrounding tissues.216 Therefore, a major focus of current
research in the biomaterials field is on the design of novel hydrogel-based cell-delivery
platforms. Overall, the goal in these strategies is to provide a cell-supportive and
bioactive microenvironment for transplanted cells to support their sustained localization,
viability and pro-regenerative secretory functions.217
Chitosan has emerged as a promising biomaterial due to its cytocompatible,
biodegradable, antimicrobial, and pro-angiogenic properties.170–172,218 The cationic nature
of chitosan supports its interactions with negatively-charged glycosaminoglycans (GAGs)
and proteoglycans, which naturally sequester growth factors and cytokines from within
the ECM.175 The innate wound healing properties of chitosan are well recognized. For
example, in a canine wound model, chitosan scaffolds were shown to enhance the
infiltration of polymorphonuclear cells, stimulate the production of collagen type III by
fibroblasts, and promote granulation tissue formation at the wound site to accelerate
wound closure.219 The immunomodulatory properties of chitosan and its oligomeric
degradation products have been postulated to be associated with its pro-regenerative
characteristics.174 More specifically, chitosan has been shown to promote macrophage
recruitment,220 as well as polarization of macrophages towards a more anti-inflammatory
(M2) phenotype that is associated with enhanced tissue regeneration.221
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Chitosan is generally insoluble in aqueous media under neutral and basic pH
conditions.177 Therefore, for cell delivery applications, chitosan is often modified to
generate glycol chitosan (GC), which is soluble in aqueous solutions at physiological
pH.140,177 Chitosan contains reactive functional groups that can serve as targets for
chemical modification, such as methacrylation, to generate N-methacrylate glycol
chitosan (MGC) that can be cross-linked to form a stable hydrogel network via UV- or
thermally-initiated cross-linking.140,178 More specifically, in previous studies in the
Amsden lab, photopolymerization of MGC has been explored using the photoinitiator
Irgacure 2959 with low intensity UV light to produce hydrogel scaffolds for tissue
engineering and growth factor delivery.140,141 Amsden et al. initially showed that MGC
with a 5% degree of substitution (DOS; methacrylate groups per 100 disaccharide units)
cross-linked with high efficiency following UV irradiation (25 mW/cm2) for 5 min.140
The hydrogels supported the viability of C-28/I2 cells (human chondrocyte cell line)
seeded on the scaffold surface over 7 days.140 A later study demonstrated that human
adipose-derived stem/stromal cells (ASCs) encapsulated in the MGC hydrogels via UVinitiated cross-linking (10.8 mW/cm2; 3 min) maintained an average viability of 62.2%
over 14 days.141 Although UV cross-linking enables rapid and efficient gelation of MGC,
the need for direct exposure to a UV light source at the site of administration limits the
clinical applicability of this approach for patients with PAD.
In the present study, a chemical initiator system consisting of ammonium persulfate
(APS) and N,N,Nʹ,Nʹ-tetramethylethylenediamine (TEMED) was used to cross-link the
MGC-based pre-polymers at 37ºC, thereby encapsulating human ASCs within the
hydrogel. This strategy allows for easy handling of the pre-polymer/cell suspension due
to the slow rate of cross-linking at room temperature, while enabling the delivery of
regenerative cells into ischemic tissues through minimally-invasive injections via a small
gauge needle. The efficacy of these initiators has been previously shown in vitro to
encapsulate rat bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) in
oligo[poly(ethelene glycol) fumarate] hydrogels.144 Similarly, Hong et al. used the
thermally-sensitive cross-linking approach to encapsulate rabbit chondrocytes in
chitosan-based gels and observed maintenance of cell number within the hydrogels over 6
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days, further confirming the cytocompatibilty of the chemical initiators.178 In addition, the
efficacy of the APS/TEMED initiator system has been demonstrated in vivo with
methacrylated hyaluronic acid (MeHA) hydrogels in an ovine myocardial infarction (MI)
model.129
Modification of scaffolds with bioactive moieties has allowed researchers to further
control the fate of transplanted cells, influencing their viability, proliferation, migration
and differentiation.222 In particular, short integrin-binding sequences derived from ECM
molecules have been explored to promote cell adhesion, retention and survival within
otherwise bio-inert scaffolds.223–225 These small peptides offer several advantages as
compared to the incorporation of complete proteins, including higher stability with
temperature and pH variations, easier characterization, and cost-effective synthesis.226,227
Building upon these concepts, one of the main objectives of the present study was to
investigate the effects of incorporating the integrin-binding RGD and IKVAV peptide
ligands on human ASC viability, retention and function following encapsulation in the
MGC hydrogels.
Due to its widespread distribution in various ECM proteins, the arginine-glycine-aspartic
acid (RGD) motif found in collagen and fibronectin is one of the most extensively studied
sequences in the biomaterials field.145 One study demonstrated that incorporating RGD
motifs within poly(ethylene glycol) (PEG) hydrogels enhanced the survival of
encapsulated human BM-MSCs, increasing the viability from 15 ± 7% to 73 ± 7% after 1
week in culture.228 In addition, BM-MSCs seeded onto the surface of the PEG-RGD
hydrogels showed improved cell attachment and spreading within 4 hours of seeding as
compared to the unmodified controls.228 Salinas et al. reported that human BM-MSCs
encapsulated in PEG hydrogels with covalently tethered RGD ligands were able to
maintain their viability at 84% over a 14-day culture period.229 In a previous study with
ASCs, rat preadipocytes were shown to bind preferentially to laminin-derived ECM
substrata as compared to fibronectin- and collagen I or IV-derived ECM substrata,166
providing a rationale for the exploration of the laminin-derived IKVAV peptide group in
the current study. While laminin-derived peptides have been less extensively explored in
the literature to date, Patel et al. demonstrated that incorporating YIGSR motifs in PEG
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hydrogels improved cell adhesion and increased cell proliferation of rat preadipocytes
seeded onto the scaffold surfaces, as evidenced by the 4.5-fold increase in DNA content
over a 6-day culture period.230
With the recognition that cell response is mediated by the biochemical and biomechanical
properties of the local cellular microenvironment,210–212 the initial experiments focused on
the physical characterization of the hydrogels. Analysis of the sol content revealed a
lower cross-linking efficiency for the MGC-IKVAV hydrogel as compared to the MGC
and MGC-RGD groups. One possible reason for this difference is that the larger IKVAV
peptide, comprised of 19 amino acids (CSRARKQAASIKVAVSADR), may have
sterically hindered the cross-linking process to a greater extent than the shorter 8 amino
acid sequence of the RGD peptide (GGGGRGDS). The 19-mer IKVAV sequence was
selected for the current study based on previous work that indicated it had favorable
bioactive effects on cells in culture.231–233 A concern with using untested shorter
sequences was that the peptides might not have an appropriate 3-D conformation to
support integrin binding. However, the length and hydrophobic nature of the 19-mer
IKVAV peptide, attributed to the relative abundance of hydrophobic alanine (A),
isoleucine (I) and valine (V) amino acid residues, may have had inhibitory effects on
cross-linking. This possibility is supported by the fact that challenges were encountered
when attempting to dissolve the MGC-IKVAV material to obtain an aqueous prepolymer solution, which necessitated blending of unmodified MGC with the peptidemodified MGC to be able to create stable gels with the MGC-IKVAV. While there were
no issues dissolving the more hydrophilic MGC-RGD pre-polymer, it was also blended in
a 40:60 ratio with unmodified MGC to ensure there were an equivalent number of peptide
moieties between the two groups for comparative purposes. While the blended prepolymers appeared macroscopically homogenous, it is possible that the more poorly
soluble MGC-IKVAV may not have incorporated into the hydrogel network as
efficiently.
The sol content is an important design consideration, as the presence of unreacted
methacrylate may negatively impact cell viability.234 However, the primary goal in
fabricating the hydrogels in the current study was to ensure that the scaffolds had similar
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equilibrium compressive moduli to assess the impact of the peptide modification of MGC
on the response of the encapsulated cell populations without the potentially confounding
biomechanical effects. Scaffold stiffness has been shown to influence cell adhesion,
cytoskeletal organization, motility and differentiation capacity.212,235,236 For example, a
previous study showed that the rate of proliferation of human dermal fibroblasts cultured
on collagen matrices was dependant on scaffold stiffness.237 Specifically, fibroblasts
seeded on stiffer matrices (143 kPa) showed an 87% increase in cell number, while there
was only a 25% increase on softer the matrices (42 kPa) over a 2-day culture period.237
For the cell culture studies, human ASCs were selected as the regenerative cell type due
to their accessibility, relative abundance, and documented capacity to secrete a broad
array of pro-angiogenic paracrine factors.93,102–104 These cells have been studied
extensively in the Flynn lab, and previous work has validated that the ASCs isolated with
the established culture protocols have multipotent differentiation capacity towards the
adipogenic, osteogenic and chondrogenic lineages.203,238 The immunophenotype analysis
of the passage 3 (P3) human ASCs used in the current study confirmed that the cells had
the expected stromal cell phenotype prior to encapsulation. The flow cytometry data was
in agreement with the International Society of Cellular Therapy (ISCT) and the
International Federation for Adipose Therapeutics and Science (IFATS) guidelines for
ASCs as a stromal cell population,112 with >80% positive stromal marker expression and
<2% negative marker expression. The variable expression of CD34 and CD146 was also
consistent with previous reports showing a steady decline in the expression of these
markers with serial passaging.100,213
Following the initial characterization of the hydrogels and ASCs, subsequent in vitro
studies focused on examining the effects of incorporating the peptide-modified MGC
formulations containing the cell-adhesive RGD or IKVAV sequences within the
hydrogels on ASC viability following encapsulation and culture under simulated hypoxic
conditions (2% O2). Notably, the unmodified MGC hydrogels supported high levels of
ASC viability over the 14-day culture period, although there was a statistically significant
decline in viability from 24 h to 14 days. In general, the viability results suggest that the
MGC base material provides a cell-supportive microenvironment, and validates the use of
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the thermally-induced cross-linking approach with APS and TEMED for ASC
encapsulation.
The investigation of the RGD-modified MGC was motivated in part by the pro-survival
effects noted in previous collaborative studies in the Amsden and Flynn labs with human
ASCs.141 More specifically, the team demonstrated that photocross-linked MGC
hydrogels grafted with the RGD peptide maintained the viability of encapsulated ASCs
above 85% over 14 days in culture under atmospheric conditions, relative to the average
viability of ~62% in the unmodified controls.141 In contrast, in the current study, the
viability in the MGC and MGC-RGD groups were quite similar. However, the MGCRGD group was the only one that demonstrated no statistically significant changes in
viability over time, suggesting that the inclusion of the RGD peptides may be favorable
for long-term ASC survival. In addition to the cross-linking approach, one key difference
with the previous study was that all culturing in the current study was performed under
simulated hypoxic conditions (2% O2), which may have enhanced the survival of the
encapsulated ASCs across all groups, including the unmodified MGC hydrogel. This
possibility is supported by the work of Stubbs et al., who showed that preconditioning
human ASCs under hypoxic conditions attenuated cell apoptosis.120
In contrast, ASC viability in the MGC-IKVAV hydrogel group was significantly reduced
at all time points as compared to the MGC and MGC-RGD groups, with 54.4 ± 12.2%
viability observed at 14 days. A possible reason for the poor initial survival of the ASCs
in the MGC-IKVAV hydrogels at 24 h could be the higher proportion of uncross-linked
methacrylate groups in this scaffold associated with the higher sol content, which may
have had adverse effects on the cells.239 More importantly, the decline in ASC viability
over 14 days indicates that the inclusion of the IKVAV peptide limited the
cytocompatibility of the MGC scaffolds. It is possible that the hydrophobic nature of the
IKVAV-containing peptide may have promoted interactions with the plasma membrane
that were detrimental to cell viability. For example, hydrophobic peptides have been
applied as cell-penetrating peptides for peptide and protein delivery.240 While past studies
using the same 19-mer IKVAV peptide have not reported impaired viability, one key
difference is that the cell response was previously explored in cells cultured on peptide67

modified 2-D surfaces.232,233 Therefore, it is possible that the interaction between the cells
and the peptide groups could vary substantially following encapsulation within a 3-D
microenvironment. Future studies could probe whether the 3-D configuration was a factor
by exploring ASC attachment and viability on the surface of pre-formed MGC-IKVAV
hydrogels in comparison to unmodified MGC controls.
Further analysis of the confocal imaging results in the viability study revealed that the
total number of ASCs within all of the hydrogel groups remained relatively constant over
the course of 14 days. These findings suggest that the ASCs did not proliferate within the
hydrogels during culture. Similar findings have been previously reported with human
ASCs encapsulated within MGC hydrogels with varying degrees of RGD
functionalization (0%, 2% and 5%), showing no differences in the number of ASCs over
a 14-day culture period.141 Likewise, Duggal et al. also demonstrated that the number of
human ASCs remained constant over 21 days when encapsulated in alginate scaffolds
covalently modified with the GRGDSP peptide sequence.241 In the future, additional
studies could be performed using complementary assays such as quantification of total
dsDNA content to validate the LIVE/DEAD® imaging results, confirming that there
were no changes in total cell number over time within the hydrogels.
The LIVE/DEAD® assay also allowed for the qualitative assessment of ASC
morphology within the hydrogels. The findings suggest that the RGD peptide promoted
ASC spreading within the superficial layers of the hydrogels, with a fraction of the
encapsulated cells in the MGC-RGD group having an elongated fibroblastic morphology
at 7 and 14 days. A previous study has reported similar findings with human BM-MSCs
seeded onto the surface of MeHA scaffolds.210 Specifically, MeHA scaffolds modified
with varying RGD peptide densities demonstrated a concentration-dependent increase in
cell adhesion and spreading area over 14 days. The study’s findings also indicated that
these morphological changes were attributed to vinculin-rich focal adhesions formed at
the periphery of the well-spread MSCs in the higher density RGD-modified MeHA
hydrogels.210 Similarly, Burdick et al. reported that PEG hydrogels modified with RGD
ligands increased osteoblast spreading within 24 h of seeding on the surface of the gels.242
Several other authors have reported similar effects in terms of cell adhesion and
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spreading when incorporating RGD ligands into various scaffolds including alginate gels,
and N-isopropylacrylamide and acrylic acid-based hydrogels.183,243
In contrast to the results observed for the MGC-IKVAV group in the current study, a
previous study showed that IKVAV peptide coatings on 2-D tissue culture polystyrene
(TCPS) increased murine myoblast attachment and spreading as compared to uncoated
controls within 3 h of seeding.244 More recently, Li et al. reported that human neural
stem/progenitor cells cultured on the surface of IKVAV-modified PEG hydrogels
displayed a spread morphology, with migration into the scaffolds observed at 7 days.245
However, a key difference is that these studies involved 2-D systems rather than 3-D cell
encapsulation, and many cell types have a more rounded morphology within 3-D in vivo
microenvironments than what is observed in 2-D culture systems.246 Another notable
difference is that Li et al. incorporated a shorter 12 amino acid sequence
(CCRRIKVAVWLC) in their PEG hydrogels, which may have interacted with the cells
differently than the peptide used in the current study. In addition, peptide conformation247
and concentration169 have also been shown to influence the interaction between cells and
the IKVAV peptides, thereby impacting cell attachment and viability. Future studies
could explore the effects of varying concentrations of the peptides, including more
detailed analysis of the structure of the cytoskeleton using immunohistochemistry to
assess differences in cell morphology. While cell spreading within the hydrogels is an
indication of altered phenotype, the effects on cell function are not yet clear and may be
an interesting area for future exploration.248
While the LIVE/DEAD® assay allowed for the direct assessment of the number of live
and dead ASCs within the hydrogels, the MTT assay was performed to probe the
metabolic activity of the encapsulated ASCs within the hydrogels. The attenuated
metabolic activity in the MGC-IKVAV group at 7 and 14 days was likely attributed to
the decline in the number of viable ASCs over the course of the study. However, while
this assay is commonly used as a measure of cell proliferation, cellular metabolic activity
can be altered for other reasons, with notable variations observed in cell responses
between 2-D and 3-D culture systems.249 For example, cells at different densities
demonstrate different metabolic activities, which may not correlate in a linear fashion.249
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The increased metabolic activity observed at 24 h for all hydrogel groups may have been
associated with the cells responding to the redox-initiated cross-linking process used for
encapsulation, with effects subsiding over time. Notably, the findings also indicated that
the metabolic activity of the encapsulated ASCs was augmented in the MGC-RGD
hydrogels at 14 days as compared to the other groups. Combined with the observed cell
spreading, this data could support that there may be differences in ASC function after
encapsulation in the MGC-RGD hydrogels at the later time points. In another study with
human BM-MSCs encapsulated within RGD-grafted alginate scaffolds, metabolic
activity initially declined over 14 days, but rebounded at 21 d to the same levels
measured at 1 d.160 Therefore, it may be interesting to explore the viability and metabolic
activity of the ASCs encapsulated in the MGC-RGD and MGC hydrogels at later time
points in future work.
With a view towards the future application of the platforms in pro-angiogenic cell
therapies for the treatment of PAD, the final in vitro studies focused on assessing the
expression of angiogenesis-associated genes in ASCs encapsulated within the hydrogels
cultured under simulated hypoxic conditions (2% O2) for 7 days relative to 2-D TCPS
controls. Overall, the most notable differences were observed between the 3-D and 2-D
culture conditions, indicating that encapsulation within the 3-D microenvironment altered
cell function. These findings are consistent with a growing body of literature that
supports that cell behavior, including proliferation, differentiation, and responses to
various stimuli, differ substantially when cells are cultured on 2-D substrates as
compared to 3-D culture systems or in vivo.250,251 For example, variations in the surface
chemistry and biomechanical properties of the 3-D hydrogels and rigid 2-D TCPS
substrates252 may have contributed to the differences in angiogenic gene expression in the
ASCs cultured on these two platforms. It is also worth noting that the ASCs cultured on
TCPS were not exposed to the free-radical initiator system with APS and TEMED, which
may have impacted ASC function. Regardless of the differences, the 2-D TCPS controls
were useful as a calibrator to normalize the gene expression levels and allow for
comparisons between the different donors.
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While this study is the first to apply a high throughput approach, these findings are
supported by previous work investigating the effects of 3-D culture conditions on proangiogenic gene expression. For example, enhanced VEGF gene expression was observed
in human ASCs seeded on polyglycolic acid/polylactic acid scaffolds relative to 2-D
culture controls at 14 and 21 days.253 Similarly, higher levels of VEGFA, HGF, FGF-2
and SDF-1 gene expression were reported in murine ASCs cultured within collagenpullulan hydrogels over 48 h as compared to TCPS controls.254
In terms of the effects of the peptide modification, with the exception of hepatocyte
growth factor (HGF), there were no statistically significant differences in the gene
expression levels of the 84 analyzed angiogenic markers between the MGC, MGC-RGD
and MGC-IKVAV hydrogel groups under the hypoxic culture conditions (2% O2) in the
current study. It is worth noting that the gene expression levels for HGF and connective
tissue growth factor (CTGF) demonstrated a >80-fold change in the hydrogel groups as
compared to the TCPS controls. However, it is also important to recognize that the
response may vary over time, and that gene expression levels do not always directly
correlate with protein expression levels. Therefore, it would be worthwhile to explore
additional time points in future work, such as the 14-day time point, where there were
notable differences in cell spreading and metabolic activity in the MGC-RGD group.
Further, it would be interesting to perform additional follow-up studies using ELISAs or
cytokine arrays to quantify secreted factors in media conditioned by encapsulated ASCs
at the protein level.
In terms of the secreted pro-angiogenic factors, there was enhanced gene expression of
HGF, vascular endothelial growth factor A (VEGFA), angiopoietin-like 4 (ANGPTL4)
and angiopoietin-2 (ANGPT2) in ASCs encapsulated in the hydrogels relative to the 2-D
controls. These factors have been shown to play key roles during vascular regeneration,
including promoting endothelial cell migration and proliferation,255 regulating vessel
permeability,256,257 and modulating wound healing.258 For example, both HGF and VEGF
can induce pro-survival effects on the endothelium under hypoxic conditions,259,260 and
angiopoietin-like 4 has been shown to promote MSC survival under hypoxic
conditions.261 The ECM-associated genes collagen XVIII α1 (COL18A1), matrix
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metalloproteinase 14 (MMP14) and integrin β3 (ITGB3) were also upregulated in the
hydrogel groups as compared to the TCPS controls, consistent with previous reports of
enhanced MMP and integrin expression in 3-D culture systems.262 Therefore, culturing
the ASCs within the hydrogels enhanced the expression of genes associated with ECM
remodeling,263,264 cell adhesion,147 and cell survival.155 For example, MMP14 has been
shown to activate other proteases including MMP2 and MMP13 to facilitate degradation
of ECM components and support vascular remodeling.263,264
While more factors were upregulated, there were several angiogenesis-associated genes
that were consistently downregulated in the ASCs encapsulated in the hydrogels relative
to the TCPS controls, including the secreted factors angiopoietin-1 (ANGPT1), CTGF
and fibroblast growth factor 1 (FGF1), which play a role in promoting endothelial cell
(EC) proliferation, migration and survival,265–268 as well as vascular stabilization.269 While
the upregulated angiopoietin-2 is associated with pro-angiogenic sprouting, angiopoietin1 reduces endothelial cell permeability and enhances vessel stabilization through mural
cell recruitment.270 As such, expression of this paracrine factor may be more critical
during the later stages of regeneration. Interestingly, gene expression of the antiangiogenic factor thrombospondin-1 (THBS1) was also downregulated in the hydrogel
groups as compared to the TCPS controls. THBS1 is a potent inhibitor of angiogenesis
that exerts its effects on EC proliferation, migration and apoptosis by antagonizing VEGF
and FGF activity.271,272 While these studies provide some preliminary insight into the proangiogenic capacity of the ASCs encapsulated within the hydrogels, further investigation
is required to probe the response over time and more fully assess the biological relevance
of these findings, including analysis of protein expression levels.
Following the in vitro studies, the hydrogels were subcutaneously implanted into
NOD/SCID mice to compare ASC retention and the induction of angiogenesis between
the MGC, MGC-RGD and MGC-IKVAV groups at 14 days. The highest cell density was
observed in the MGC-RGD implants, which was significantly different than the MGCIKVAV group. These results are consistent with the in vitro findings that indicated that
long-term viability was impaired in the MGC-IKVAV group and improved in the MGCRGD. In comparing the MGC and MGC-RGD groups, a relatively high density of
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encapsulated ASCs could be visualized in both groups, suggesting that the hydrogels also
supported local cell retention. Based on the observed trends, it is possible that increasing
the peptide concentration beyond 2.5% in the MGC-RGD group could further augment
cell adhesion and retention, as concentration-dependent effects on cell viability and
attachment have been previously reported with human BM-MSCs encapsulated in RGDmodified HA hydrogels.210
As a surrogate measure of tissue revascularization, subsequent analyses focused on
assessing murine CD31+ cell recruitment and proliferation in the peri-implant regions. In
comparing the unseeded hydrogel groups, the findings suggest that all of the hydrogels
promoted similar levels of CD31+ cell recruitment, which may be attributed to the proregenerative nature of the MGC base material, as discussed previously.170–172,218 For
example, the pro-angiogenic qualities of chitosan were shown in a previous study where
EC recruitment and vascularization were enhanced in the periphery of collagen-chitosan
composites implanted subcutaneously in mice as compared to collagen-only controls.273
In assessing the ASC-seeded groups, CD31+ cell recruitment was significantly enhanced
in the peri-implant region of the ASC-seeded MGC and MGC-RGD groups as compared
to the unseeded controls. These findings suggest that ASCs encapsulated within these
hydrogels secreted paracrine factors that promote CD31+ cell migration to the implant
interface. Similar pro-angiogenic paracrine effects have been previously reported with
autologous BM-MSCs delivered in HA scaffolds in a subcutaneous rat model,274 as well
as with human ASCs delivered on collagen scaffolds in a nude rat model.275 The
consistency in the CD31+ cell recruitment frequencies in the MGC and MGC-RGD
groups is concordant with the similar viability and angiogenic gene expression profiles
observed for these two groups in the in vitro studies. In contrast, the lack of ASCmediated cell recruitment observed in the MGC-IKVAV implants is consistent with the
in vitro findings that cell viability was lower in this group. Analysis of cell proliferation
within the peri-implant region through semi-quantitative measurement of CD31+ EdU+
cells was suggestive of pro-angiogenic processes being induced in all of the groups.
Overall, these in vivo findings support that the MGC and MGC-RGD hydrogels are
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promising platforms for ASC delivery to promote local cell retention, viability, and
beneficial paracrine factor production for applications in therapeutic angiogenesis.
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Chapter 5

5

CONCLUSIONS

As the prevalence of peripheral artery disease (PAD) in North America rises, current
treatments and surgical interventions remain limited in their efficacy to stimulate new
blood vessel growth, restore long-term perfusion and promote functional recovery in the
affected limb(s).1,4,14 As such, there is a critical need for new clinically-translatable
therapies that enhance perfusion in the affected tissues, minimize the risk of disease
progression and improve the quality of life for patients with PAD. First generation cellbased therapies involving the injection of mesenchymal stem/stromal cell (MSC)
suspensions into ischemic tissues have shown potential for stimulating new blood vessel
formation.58–60 However, the poor survival and retention of transplanted cells limits the
pro-regenerative and pro-angiogenic functions of MSCs at the target ischemic sites.85–87
To address these issues, the current project investigated an integrative approach
combining cell-based therapy with a scaffold-based cell delivery strategy. Specifically,
the survival and function of human adipose-derived stem/stromal cells (ASCs) was
examined following encapsulation in N-methacrylate glycol chitosan (MGC) hydrogels.
To further tune the approach, the MGC polymer was modified with integrin-binding
RGD or IKVAV peptide ligands to assess the effects of these bioactive moieties in
promoting ASC viability, retention and function within the hydrogels.

5.1 Summary of Findings
Prior to the cell-encapsulation studies, the initial experiments focused on characterizing
the hydrogel scaffolds and the passage 3 (P3) human ASCs. While the sol content
revealed that the MGC and MGC-RGD groups had a higher cross-linking efficiency than
the MGC-IKVAV group, the equilibrium compressive moduli across all groups were
similar, thus confirming consistent biomechanical properties which could potentially
impact cell function. The immunophenotype analysis confirmed that the P3 ASCs aligned
with the guidelines set forth by the International Society of Cellular Therapy (ISCT) and
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the International Federation for Adipose Therapeutics and Science (IFATS) for stromal
cell population.112
For aim 1, in vitro analyses were conducted to assess ASC viability, cell morphology and
metabolic activity following cell encapsulation within the MGC, MGC-RGD or MGCIKVAV hydrogels over 14 days in culture under hypoxic culture conditions (2% O2)
simulating the ischemic limb. The results demonstrated that ASCs encapsulated in the
MGC and MGC-RGD hydrogels were able to maintain high viability (>75% and >80%,
respectively) over the 14-day culture period. Notably, the MGC-RGD group was the only
group that did not show a significant decline in ASC viability over the course of the
study, suggesting that the incorporation of the RGD peptide supported long-term cell
viability. In contrast, poor viability was noted in the MGC-IKVAV group, suggesting that
the selected peptide was not conducive for promoting ASC viability or retention
following encapsulation in the 3-D MGC-based hydrogel system. The assessment of cell
morphology showed that ASCs encapsulated in the MGC and MGC-IKVAV hydrogels
maintained a rounded shape over the course of the study. In contrast, ASCs encapsulated
in the MGC-RGD hydrogels presented a more elongated fibroblastic morphology within
the superficial layers at 7 and 14 days in culture, providing evidence for cell-scaffold
interactions between the ASCs and RGD motifs. The metabolic activity of the
encapsulated ASCs declined between 24 h and 7 days for all hydrogel groups, and was
then maintained throughout the course of the study. In addition, the metabolic activity
was enhanced in the MGC-RGD group as compared to the MGC and MGC-IKVAV
groups at 14 days, suggesting that the RGD peptide ligand may influence the metabolic
functions of encapsulated ASCs over time.
For aim 2, ASC function was probed in vitro by comparing the expression of
angiogenesis-associated genes between ASCs encapsulated in the hydrogels versus 2-D
tissue culture polystyrene (TCPS) controls cultured under simulated hypoxic conditions
(2% O2) for 7 days. In general, the most notable differences were associated with
culturing the ASCs in the 3-D hydrogels versus the 2-D culture conditions across all 4
cell donors. More specifically, ASCs encapsulated in the hydrogels demonstrated a >2fold upregulation in gene expression for the secreted angiogenic factors hepatocyte
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growth factor (HGF), vascular endothelial growth factor A (VEGFA), angiopoietin-like 4
(ANGPTL4) and angiopoietin-2 (ANGPT2) relative to the TCPS controls. Furthermore,
the extracellular matrix (ECM) protein collagen XVIII α1 (COL18A1), the matrixremodeling factor matrix metalloproteinase 14 (MMP14), and the cell adhesion
glycoprotein integrin β3 (ITGB3) also demonstrated a >2-fold enhancement in gene
expression in the hydrogel groups relative to the TCPS controls. In contrast, a >2-fold
downregulation in gene expression was consistently noted across all 4 cell donors for the
secreted factors thrombospondin-1 (THBS1), angiopoetin-1 (ANGPT1), connective tissue
growth factor (CTGF) and fibroblast growth factor 1 (FGF1) in the ASCs encapsulated in
the hydrogels as compared to the TCPS controls. While transcription for the majority of
the analyzed angiogenic factors was not considerably influenced by the presence of the
RGD or IKVAV peptides under the conditions in the study, these preliminary findings
suggest that the 3-D microenvironment of the MGC hydrogel induced transcriptional
changes in the ASCs under hypoxic conditions that may be favorable for a proangiogenic response.
For aim 3, cell retention and angiogenic-induction potential of ASCs encapsulated within
the hydrogels was assessed in vivo after subcutaneous implantation into NOD/SCID mice
for 14 days. A significantly higher number of ASCs were retained in the MGC-RGD
hydrogels relative to the MGC-IKVAV hydrogels, consistent with the in vitro viability
studies. While there was a trend for enhanced retention in the MGC-RGD group as
compared to the MGC group, the difference was not statistically significant. These
findings suggest that the base MGC scaffold alone provided a supportive
microenvironment for ASC retention in vivo over the course of the study. With respect to
the pro-angiogenic potential, ASC-seeded MGC and MGC-RGD groups enhanced
murine CD31+ cell recruitment within the peri-implant region as compared to their
corresponding unseeded controls, suggesting that the hydrogels were able to support the
paracrine functions of ASCs to help establish accessory cell recruitment, a characteristic
of a more pro-angiogenic microenvironment. In contrast, there was no difference in
CD31+ cell recruitment between the ASC-seeded and unseeded MGC-IKVAV group,
potentially due to the low cell viability and retention within these hydrogels. Assessment
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of CD31+ EdU+ cells in the peri-implant region indicated that CD31+ cell proliferation
was ongoing in all of the groups. Altogether, these findings suggest that the MGC and
MGC-RGD hydrogels provide a cytocompatible microenvironment, supportive of ASC
retention and accessory cell recruitment in vivo.
The collective findings highlight the potential of the MGC and MGC-RGD hydrogels as
cell-delivery platforms, capable of supporting the viability, retention and sustained
function of encapsulated ASCs. In addition, evidence of the pro-angiogenic capacity of
encapsulated human ASCs was provided through the in vitro and in vivo studies, lending
support for their use in therapeutic applications to promote vascular regeneration.
Ultimately, the work presented in this thesis contributes to the fields of stem/stromal cell
biology, biomaterials and therapeutic angiogenesis.

5.2 Future Recommendations
Although the current project offers insight into the development of an injectable celldelivery platform for therapeutic angiogenesis, future studies should focus on optimizing
the ASC viability, retention and function following encapsulation in the hydrogels.
Continued refinement of the functionalization of the MGC hydrogels with peptides
incorporating the RGD or IKVAV bioactive motifs, complemented with in vitro and in
vivo studies to further assess ASC behaviour within the hydrogels, could help to establish
a more effective cell-delivery vehicle.
Previous studies have provided support for the IKVAV peptide in promoting cell
attachment and proliferation.165,169,244 However, the current findings suggest that the
inclusion of the 19-mer IKVAV peptide in the MGC hydrogels adversely impacted
hydrogel cross-linking and the viability of encapsulated ASCs. Therefore, it would be
beneficial to examine whether adjusting the length and/or hydrophobicity of the IKVAV
peptide could provide a 3-D conformation that improves the ASC survival and better
supports integrin-mediated cell attachment within the hydrogels. In addition, future
studies could investigate the degree of RGD or IKVAV functionalization of the MGC
hydrogels over a boarder range (e.g. 2.5%, 5%, and 10%), in order to delineate any
concentration-dependent trends on ASC attachment, viability and metabolic function, as
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observed in previous reports.141 Collectively, these studies will help to establish the
appropriate peptide sequence and concentration required to improve ASC adhesion and
retention within the hydrogels.
The confocal imaging of ASCs encapsulated in the hydrogels in the current study allowed
for the macroscopic assessment of ASC morphology following culture. Future studies
should include more detailed immunohistochemial analysis to examine the changes in the
cytoskeleton structure of the encapsulated ASCs. For example, ASCs could be stained for
actin and vinculin at various time points (e.g. 7, 14 and 28 days), and analyzed through
confocal imaging to validate the trends by more fully assessing cell spreading and focal
adhesion formation. In order to better understand the regulation of integrins in ASCs
during cell attachment, it would be of interest to examine the expression of various
integrin subunits (e.g. α1, αV, β3, etc.) through immunohistochemical staining. This
study may help define the predominant α/β subunits involved in the cell-scaffold
interactions due to the presence of integrin-binding RGD or IKVAV motifs.
While the metabolic activity of ASCs encapsulated in the hydrogels showed an initial
decline across all groups, a rebounding trend was observed in the MGC-RGD group by
day 14. Future studies should more fully probe this response by assessing the ASC
metabolic activity at later time points (e.g. 28 days) to determine whether the bioactive
peptide ligands in the hydrogels significantly enhance metabolic functions following
long-term culture. In addition, the total dsDNA content in the ASC-encapsulated
hydrogels should be assessed using the Quant-iT PicoGreen® dsDNA assay in order to
validate the current semi-quantitative imaging data regarding the total cell number, and
more fully assess whether the ASCs may be proliferating within the scaffolds, potentially
in combination with Ki67 immunohistochemical staining.
The high-throughput screening of the angiogenesis-associated genes in the ASCs
encapsulated within the hydrogels showed that the expression levels of several key proangiogenic genes were altered as compared to TCPS controls. Future studies could
further probe the relevant genes through real-time RT-PCR and Western blotting of
protein lysates to determine their regulation over the course of 14 or 28 days. The
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conditioned medium from culturing the ASC-encapsulated hydrogels could also be
examined through MultiPlex ELISA or proteomics analyses to assess whether detectable
levels of factors are being secreted from the hydrogels over time. Furthermore, for a more
controlled comparison between 3-D and 2-D culture conditions, future studies could
probe the angiogenic response of ASCs seeded onto the surface of MGC, MGC-RGD or
MGC-IKVAV hydrogels. Collectively, these studies would provide an in-depth analysis
of the angiogenesis-associated secretory factors at the transcriptional and protein level.
MSCs have been previously shown to maintain the expression of typical stromal cell
markers following prolonged 2-D culture conditions.276 It would be of interest to
investigate the MSC phenotype of ASCs following 3-D culture within the hydrogels.
More specifically, the mRNA could be extracted from donor-matched ASCs prior to the
encapsulation process, as well as after culture in the hydrogels for 14 or 28 days. The
MSC marker expression could then be analyzed using a Human Mesenchymal Stem Cell
RT2 Profiler™ PCR array to compare the stem-cell state of ASCs prior to and following
3-D culture within the hydrogels.
In terms of future in vivo work, the efficacy of the injectable ASC delivery strategy
should be investigated in a murine femoral artery ligation (FAL)-induced hindlimb
ischemia model.208 More specifically, ASC-loaded hydrogels could be injected
intramuscularly into the hindlimb of NOD/SCID mice following FAL-induced hindlimb
ischemia. Thereafter, the mice could be assessed in terms of limb reperfusion via Laser
Doppler Perfusion Imaging (LDPI), functional limb improvement using a CatWalk™
system, and revascularization through more detailed immunohistochemical (CD31 and
von willebrand factor) analysis. In addition, NOD/SCID/mucopolysaccharidosis type VII
(MSPVII) mice could be used in a similar hindlimb ischemic model to allow for the more
sensitive detection of transplanted viable ASCs in the ischemic tissue, as these mice lack
beta-glucoronidase (GUSB) activity that is ubiquitously expressed in human cells.208 This
approach would enable the assessment of ASCs using a calorimetric substrate for GUSB
in order to localize viable transplanted cells, at single cell resolution, within or around the
new blood vessel growth. Together, these investigations would aid in understanding the
potential of the MGC-based ASC-delivery strategy to retain the transplanted cells,
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promote angiogenesis, and facilitate functional recovery of ischemic tissues, as a nextstep towards clinical translation.
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